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ABSTRACT 
 
 
 Genital Chlamydia trachomatis infection is a major public health concern. 
Chlamydia is the most commonly reported infection in the United States and the most 
common bacterial sexually transmitted infection worldwide. Unrecognized infection 
endangers female reproductive health by serious complications such as Pelvic 
Inflammatory Disease, ectopic pregnancy, and involuntary infertility. Widespread 
Chlamydia control programs were implemented more than two decades ago to improve 
women’s reproductive health but, despite initial success, the number of chlamydial 
infections reported have increased.  
 
One of the hypotheses put forth to explain increased chlamydial reporting 
suggests that a long-term caveat of control initiatives is interference with the 
development of natural occurring immunity as a result of mass screening and rapid 
treatment. It is proposed that human cohorts are more susceptible to subsequent 
chlamydiae infection and their increased susceptibility drive the current increase in 
sexually transmitted chlamydiae case notifications. 
 
In these studies we describe a comprehensive approach to assessing the role of 
early anti-chlamydial intervention, an integral component of control initiatives, on the 
subsequent development and severity of upper genital tract sequelae in a murine model of 
recurrent chlamydiae urogenital infection. The development of an in vivo model of 
urogenital Chlamydia trachomatis infection is central to defining the risk of developing 
long term reproductive complications, delineating potential biomarkers for chlamydial-
induced genital tract disease, interrogating host factors that may contribute to the 
development of adverse complications, and anti-chlamydial vaccine development.  
  
vii 
TABLE OF CONTENTS 
 
CHAPTER 1. CHLAMYDIAE .........................................................................................1 
Historical Perspective ....................................................................................................1 
Taxonomy ......................................................................................................................1 
Developmental Cycle .....................................................................................................2 
Chlamydiae Clinical Significance ..................................................................................4 
Chlamydia pneumoniae .............................................................................................4 
Chlamydia psittaci .....................................................................................................4 
Chlamydia trachomatis ..............................................................................................6 
Ocular Chlamydia trachomatis ..................................................................................6 
Genital Chlamydia trachomatis .................................................................................6 
Mouse Model of Genital Infection .................................................................................7 
Murine Genital Tract Pathology ................................................................................9 
Murine Model Limitations .........................................................................................9 
Immunological Response to Genital Infection ............................................................11 
Intracellular Immune Response Overview...................................................................11 
Chlamydia Innate Response .....................................................................................11 
Chlamydia Adaptive Response ................................................................................12 
Vaccination ..............................................................................................................13 
Control Measures .........................................................................................................14 
Sexually Transmitted Chlamydia Epidemiology .....................................................15 
Hypotheses for Rebounding Chlamydia Rates ........................................................16 
Arrested Immunity Hypothesis ................................................................................18 
Dissertation Rationale ..................................................................................................19 
CHAPTER 2. ARRESTED IMMUNITY: IMPACT OF EARLY TREATMENT 
ON UPPER GENITAL TRACT SEQUELAE ..............................................................20 
Introduction ..................................................................................................................20 
Materials and Methods .................................................................................................21 
Mice .........................................................................................................................21 
Chlamydia Strain and Titration ................................................................................21 
Mouse Infection .......................................................................................................21 
Antibiotic Treatment ................................................................................................21 
Bacterial Shedding ...................................................................................................21 
Fluorescence-Linked Immunosorbent Assay (FLISA) Antibody Analysis .............22 
Pathology .................................................................................................................22 
Organ-Total Body Weight Ratio Analysis ...............................................................22 
Statistical Analysis ...................................................................................................23 
Results ..........................................................................................................................23 
Kinetics of Genital Tract Infection in Antibiotic-Treated Mice ..............................23 
Immune Arrest and Pathology Following Primary Infection of Antibiotic-
Treated Mice ............................................................................................................23 
Disease Severity Following Reinfection in Antibiotic-Treated Mice .....................26 
viii 
IL-4 Is Detectable Late Following Reinfection and Positively Correlates with 
Disease Severity in Antibiotic-Treated Mice ...........................................................31 
Chlamydia and Cellular Infiltrates Following Reinfection in Antibiotic-Treated 
Mice ..........................................................................................................................31 
Discussion ....................................................................................................................36 
CHAPTER 3. CHLAMYDIAL GENITAL TRACT SEQUELAE IS AGE AND 
STRAIN-DEPENDENT ..................................................................................................42 
Introduction ..................................................................................................................42 
Materials and Methods .................................................................................................42 
Mice .........................................................................................................................42 
Chlamydia Strain .....................................................................................................43 
Chlamydia muridarum Infection .............................................................................43 
Pathology Assessment .............................................................................................43 
Results ..........................................................................................................................44 
C57BL/6J Exhibit Age-Dependent Upper Genital Tract Sequelae Post-Primary 
Intravaginal Infection ...............................................................................................44 
Secondary Intravaginal Infection Exacerbates Chlamydial-Induced Upper 
Genital Tract Complications ....................................................................................44 
C57BL/6 Mice Are More Susceptible to Chlamydial-Induced Upper Genital 
Tract Complications When Compared to DBA/2J Mice .........................................44 
Discussion ....................................................................................................................47 
CHAPTER 4. IMMUNIZATION WITH C. MURIDARUM OUTER 
MEMBRANE COMPLEX FAILS TO PROTECT AGAINST UPPER 
GENITAL TRACT COMPLICATIONS IN A MURINE MODEL OF 
GENITAL INFECTION .................................................................................................50 
Introduction ..................................................................................................................50 
Materials and Methods (Systemic Lethal Model) ........................................................51 
Mice .........................................................................................................................51 
Chlamydiae ..............................................................................................................51 
COMC Extraction ....................................................................................................51 
Immunization and Infection .....................................................................................52 
Results (Systemic Lethal Model) .................................................................................52 
Materials and Methods (Urogenital Model) ................................................................55 
Mice .........................................................................................................................55 
Chlamydiae ..............................................................................................................55 
COMC Extraction ....................................................................................................55 
Immunization and Infection .....................................................................................55 
Results (Urogenital Model) ..........................................................................................56 
Materials and Methods (Alum Study)..........................................................................56 
Mice .........................................................................................................................56 
Chlamydiae ..............................................................................................................56 
Immunization and Infection .....................................................................................59 
Pathology Assessment .............................................................................................59 
ix 
Results (Alum Study) ...................................................................................................59 
Immunogens without Intravaginal Chlamydia muridarum Challenge Do Not 
Induce Severe Upper Genital Tract Sequelae Formation .........................................59 
Alum Alone Does Not Negate the Development of Severe Upper Genital Tract 
Complications ...........................................................................................................63 
Discussion ....................................................................................................................63 
CHAPTER 5. CONCLUSIONS ......................................................................................68 
Testing the IL-4 Hypothesis.........................................................................................68 
Identifying Genetic Link to Age-Dependent Disease Severity....................................68 
Implications for Vaccine Development .......................................................................69 
LIST OF REFERENCES ............................................................................................... 70 
APPENDIX A. MORBIDITY AND PATHOLOGY SEVERITY POST- 
PRIMARY INFECTION IN DEFERRED TREATMENT STUDIES .......................91 
APPENDIX B. MORBIDITY AND PATHOLOGY SEVERITY POST- 
SECONDARY INFECTION IN DEFERRED TREATMENT STUDIES .................92 
APPENDIX C. TH1-RELATED CYOKINES POST RECURRENT     
INFECTION IN ARRESTED IMMUNITY MODEL..................................................93 
APPENDIX D. TH2-RELATED CYTOKINES POST RECURRENT  
INFECTION IN ARRESTED IMMUNITY MODEL..................................................94 
VITA................................................................................................................................. 95 
 
 
 
  
x 
LIST OF TABLES  
 
Table 1-1. Chlamydiae that cause human disease. ...........................................................5 
Table 1-2. Increased chlamydial rate hypotheses. ..........................................................17 
 
 
  
xi 
LIST OF FIGURES 
 
Figure 1-1. Chlamydiae developmental cycle. ..................................................................3 
Figure 2-1. Shedding of viable C. muridarum following intravaginal challenge. ...........24 
Figure 2-2. C57BL/6 pathology severity scores 49 days post-primary C. muridarum 
intravaginal infection. ..................................................................................25 
Figure 2-3. Total Immunoglobulin G (IgG) antibody response 49 days post-primary 
C. muridarum intravaginal infection. ...........................................................27 
Figure 2-4. Immunoglobulin G (IgG) isotype responses 49 days post C. muridarum 
intravaginal infection in mice intraperitoneally treated with doxycycline...28 
Figure 2-5. Incidence and severity of upper genital tract sequelae in antibiotic- 
treated mice 28 days post-secondary infection. ...........................................29 
Figure 2-6. Incidence and severity of uterine horn and oviduct sequelae in antibiotic-
treated mice 28 days post-secondary infection. ...........................................30 
Figure 2-7. Weight ratio verses total severity score correlative analysis. .......................32 
Figure 2-8. Comparative analysis of weight ratios post-primary and secondary 
sacrifice in untreated intravaginally infected C57BL/6 mice. .....................33 
Figure 2-9. Systemic IL-4 post recurrent infection. ........................................................34 
Figure 2-10. Neutrophil infiltrates post-secondary infection. ...........................................35 
Figure 2-11. Mast cell infiltrate post-secondary infection.................................................37 
Figure 2-12. Mast cell infiltrate verses systemic IL-4 correlative analysis. ......................38 
Figure 2-13. Eosinophil infiltrate post-secondary infection. .............................................39 
Figure 3-1. Upper genital tract disease incidence and severity post-primary 
infection........................................................................................................45 
Figure 3-2. Upper genital tract disease incidence and severity post-secondary 
infection........................................................................................................46 
Figure 3-3. Weight ratio disease severity validation post-primary and secondary 
intravaginal infection. ..................................................................................48 
Figure 4-1. High dose 6BC C. psittaci systemic infection survival curve. .....................53 
Figure 4-2. Low dose 6BC C. psittaci systemic infection survival curve. ......................54 
xii 
Figure 4-3. Comassie stained SDS-Page gel of C. muridarum (MoPn)-derived 
COMC and C. psittaci (6BC)-derived COMC preparations. .......................57 
Figure 4-4. C. muridarum-derived COMC immunization study gross pathology. .........58 
Figure 4-5. Alum study experimental timeline. ...............................................................60 
Figure 4-6. Oviduct pathology severity of non-challenged immunized groups. .............61 
Figure 4-7. Uterine horn pathology severity of immunized, non-challenged groups. .....62 
Figure 4-8. Oviduct pathology severity of immunized and challenged groups. ..............64 
Figure 4-9. Uterine horn pathology severity of immunized and challenged groups. ......65 
 
 
 
 
  
xiii 
LIST OF ABBREVIATIONS 
 
 
APC Antigen-presenting cells  
CDC Centers for Disease Control and Prevention  
Cpn Chlamydia pneumoniae 
Ct Chlamydia trachomatis  
DC Dendritic cell 
EB Elementary bodies 
ELISA Enzyme-linked immunosorbent assay 
FLISA Fluorescent-linked immunosorbent assay 
GM-CSF Granulocyte-macrophage coloy-stimulating factor 
H&E Hematoxylin and eosin stain 
HPV Human papillomavirus 
HSP  Heat shock protein  
IACUC Institutional Animal Care and Use Committee 
IFN Interferon 
IFU Inclusion-forming units 
IgG Immunoglobulin G 
IL Interleukin  
LD50 Lethal dose, 50% 
LGV Lymphogranuloma venereum  
LPS Lipopolysaccharide 
MHC Major histocompatibility complex 
MOMP Major outer membrane protein  
MoPn Chlamydia muridarum  
NAAT Nucleic acid amplification testing  
PAMP  Pathogen-associated molecular pattern 
PID Pelvic inflammatory disease 
PMN Polymorphonuclear leukocyte 
PRR Pattern recognition receptor  
RB Reticulate bodies  
RPM Rotations per minute 
SD Standard deviation 
STD Sexually transmitted disease 
STI  Sexually transmitted infection 
TH0 Naive T Cells 
TH1 T Helper 1 Cells  
TH2 T Helper 2 Cells  
TNF Tumor necrosis factor 
UGT  Upper genital tract 
WHO World Health Organization 
 
 
 
1 
CHAPTER 1.    CHLAMYDIAE 
 
 
Historical Perspective 
Tales as old as time . . . .  
-Howard Ashman and Alan Menken 
 
Descriptions of chlamydial disease date back to ancient Chinese and Egyptian 
texts detailing trachoma, a blinding chlamydial ocular disease. In 2002 Dimitrakov 
reviewed the expedition in which Ludwig Halberstaedter and Stanislaus von Prowazek 
discovered the causative agent of trachoma [1].  In 1907, while on the island of Java, 
Halberstaedter and von Prowazek pioneered early chlamydial etiology studies by 
inoculating orangutans with material obtained from trachoma patients. They were able to 
demonstrate the infectious nature of the pathogen by describing intracellular vacuoles in 
Giemsa-stained epithelial cells derived from conjunctival scrapings of the infected 
animals but incorrectly characterized the agent as protozoan.  
 
In 1910, Linder reported finding the same type of intracytoplasmic inclusions in 
the eyes of neonates and linked their neonatal conjunctivitis to intrapartum exposure in 
women with unrecognized and untreated infection.  Linder went on to speculate that the 
infection was transmitted sexually after identifying inclusion bodies in the mother’s 
cervical scrapings, urethral cells from the fathers, and in individuals with non-
gonnococcal uretheritis [2] [3] [4]. 
 
In the 1930’s Samuel Bedson and colleagues characterized the developmental 
cycle of psittacosis particles, which at the time were thought to be viruses given their 
dependence on eukaryotic cells for replication. In 1957, fifty years after the Java 
excursion, C. trachomatis was successfully isolated and cultured in yolk sacs by Feifan 
T’ang et al [5] [6].  It was not until the mid 1960’s that chlamydiae would be defined as 
prokaryotic bacteria that possessed a non-infectious intracellular replication phase [7]. In 
1969, Gordon et al described culturing chlamydiae in irradiated McCoy cells, a less time 
consuming technique alternative to isolating chlamydiae in yolk sac that would 
revolutionize diagnostic procedures for chlamydial infection [8].  
 
 
Taxonomy 
What is in a name? 
–William Shakespeare 
  
Chlamydiae are prokaryotic obligate intracellular bacteria that belong to the order 
Chlamydiales. Under the Chlamydiale umbrella are the families Chlamydiaceae, 
Parachlamydiaceae, Waddliaceae, and Simkaniaceae [9]. In 1999, it was recommended 
that the Chlamydiaceae family be subdivided into two genera, Chlamydia and 
Chlamydophila, based on the phylogenetic analysis of the 16s and 23s rRNA [10] but this 
recommendation was riddled with inconsistencies and controversial amongst those in the 
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chlamydial field. As reviewed by Stephens and colleagues [11], the overwhelming 
majority of publications (81% in the year 2006), continued to use the single genus name 
Chlamydia, despite the implementation of the two genera system.  To that end, nine 
species are recognized in the Chlamydia genus: Chlamydia abortus, Chlamydia caviae, 
Chlamydia felis, Chlamydia muridarum, Chlamydia pecorum, Chlamydia pneumoniae, 
Chlamydia psittaci, Chlamydia suis, and Chlamydia trachomatis. Historically, 
chlamydiae serovars were based on conventional immunoepitiope analysis by 
monoclonal antibody directed against the major outer membrane protein (MOMP) [12]. 
Today, chlamydial classification includes genovar sequence data of ompA, the gene that 
encodes MOMP [13] [14]. The ompA-based classifying system, when compared to the 
conventional sera-based analysis, more accurately reflects strain virulence and genotypic 
diversity on the population level [15]. 
 
 
Developmental Cycle 
In the circle, the circle of life. 
–Sir Timothy Miles Bendon Rice 
 
 Originally described in the 1930’s by Samuel Bedson et al [16], the unique 
biphasic developmental cycle of chlamydiae has been extensively reviewed [17] [18] [19] 
[20] [21] [22]. Two morphologically different forms characterize the chlamydial 
developmental cycle, the elementary body (EB) and the reticulate body (RB).  The 
elementary body is the infectious form of the organism.  Although small in size, about 0.2 
to 0.4 microns in diameter, EBs are resistant to extracellular conditions and are able to 
attach and enter susceptible host cells. Once endocytosed into the host cell, EBs 
differentiate into RBs inside a membrane bound vacuole called an inclusion. Reticulate 
bodies are the metabolically active and non-infectious intracellular forms of chlamydiae 
which multiply via binary fusion within the inclusion. After repeated cycles of cell 
division, RBs undergo a second differentiation stage resulting in infectious chlamydial 
EBs. Depending on the Chlamydia species, infectious progeny exit the initially infected 
cell between 30-72 hours post infection and infect neighboring host cells (Figure 1-1).  
 
For millions of years Chlamydia species have infected eukaryotic cells and many 
researchers believe that they have ensured their survival by deviating from their normal 
biphasic developmental cycle. Persistence, a reversible interruption in the productive 
intracellular chlamydial growth cycle by environmental factors, has been reviewed many 
times over [23] [24] [25] [26] [27] and is characterized by large aberrant non-replicating 
RBs which are unable to alternate between EB and RB morphological forms. In vitro 
inducers of this abnormal growth state include physiological changes in the host cell, 
gamma interferon treatment [28] [29] [30] [31] [32], beta lactam administration [33] [34] 
[35], nutrient restriction [36] [37] [38] [39] [40], and concurrent herpes infection [41] 
[42] [43]. By definition, restoration of normal chlamydiae development occurs when the 
environmental stressor that induced the persistent state is removed. While the likelihood 
of persistence being involved in chlamydiae-induced pathogenesis has been documented 
in a variety of culture-based systems, particularly as it relates to antibiotic treatment and   
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Figure 1-1. Chlamydiae developmental cycle. 
 
Note: Chlamydiae share a unique biphasic developmental cycle consisting of the 
following steps: 1) Attachment and entry of the infectious Elementary Body (EB) form 2) 
Primary differentiation from the infectious EB form to the metabolically active but non-
infectious Reticulate Body (RB) form in a cytoplasmic vacuole called an inclusion 3) 
Cell division by binary fission 4) RB genomic replication 5) Secondary differentiation 
from RB to EB and 6) Cell lysis/endocytosis and release of infectious progeny. 
Chlamydiae may enter an abnormal state of growth called persistence under the selective 
pressure of a variety of inducers. Chlamydiae re-enter the cycle and resume normal 
development when the selective inducer is removed.  
  
1. Attachment and 
Entry 
2. Primary  
Differentiation  
3. Cell  
Division  
4. Genomic Replication  
5. Secondary  
Differentiation  
6. Release   
Persistence   
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host immunological pressures, conclusive evidence of human chlamydial persistence 
remains to be demonstrated.  
 
 
Chlamydiae Clinical Significance 
 Chlamydial infection is of global importance given its broad host tropism, the 
scope of its geographic distribution, and the risk of developing debilitating sequelae. Of 
the nine Chlamydia species, three are known to cause a diverse spectrum of diseases in 
human populations: Chlamydia pneumoniae, Chlamydia psittaci, and Chlamydia 
trachomatis (Table 1-1).  
 
 
Chlamydia pneumoniae 
 
So you’re telling me that you can catch Chlamydia by just breathing?  There goes the 
neighborhood. 
–Corey Dannard 
 
 Chlamydia pneumoniae was introduced as a novel member of the genus 
Chlamydia by Grayston et al in 1989 and is commonly associated with upper respiratory 
infections.  C. pneumoniae causes approximately ten percent of community-acquired 
pneumonia and five percent of pharyngitis, bronchitis, and sinusitis [44]. In addition, 
strong associations exist between C. pneumoniae infection and atherosclerosis, a chronic 
cardiovascular disease whose complications lead to half of the adult deaths in the United 
States and other parts of the western world (Reviewed by Belland et al [45]). It is 
important to note that the association between Chlamydia pneumoniae and 
atherosclerosis is a point of debate given the failure to improve clinical outcomes with the 
administration of antichlamydial antibiotics in large scale clinical trials including patients 
with cardiovascular disease [46] [47] [48].  
 
 
Chlamydia psittaci  
 
You do know, of course, that zoonotic doesn’t mean the viruses came from the zoo. 
–Law and Order: Criminal Intent 
 
 Chlamydia psittaci, a zoonotic pathogen whose natural reservoir is avian, is 
recognized by the Centers for Disease Control and Prevention as a category B select 
agent due to the ease of respiratory dissemination and associated morbidity and mortality 
rates [49] [50]. As reviewed by Harkinezhad and colleagues, human C. psittaci infection 
is called psittacosis and is acquired by inhalation or, to a lesser extent, ingestion of bird 
excretions [51]. After inhalation, the organism infects the respiratory epithelium and 
remains latent for up to three weeks void of clinical symptoms. Following the incubation 
period those infected experience flu-like symptoms such as headaches, chills, fever, 
cough, and in rare instances, neurological and cardiac-related complications. In extreme, 
untreated cases the infection can be fatal.   
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Table 1-1. Chlamydiae that cause human disease.  
 
Species Serovar Acute Disease Sequelae 
C. pneumoniae   Community-
Acquired 
Pneumonia  
Arthritis 
  Sinusitis Asthma  
  Bronchitis  Arthrosclerosis* 
  Pharyngitis  
    
C. psittaci   Atypical Pneumonia Potentially Fatal  
  Renal and Hepatic 
Complication  
 
    
 C. trachomatis  A, B, C Conjunctivitis  Trachoma  
 D,E,F,G,H,I,J,K Cervicitis, Urethritis Pelvic Inflammatory 
Disease (PID) 
   Ectopic Pregnancy  
   Involuntary 
Infertility  
   Reiter’s Syndrome 
 LGV Lymphogranuloma 
venereum (Bubonic) 
Fitz-Hughes-Curtis 
Syndrome 
Note: * indicates debated chlamydial-sequelae association. 
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Chlamydia trachomatis  
 
Chlamydia trachomatis is composed of four biovars, biological strains, based on 
the target cells they infect and whole genome sequencing [52] [53] [54].  As implied by 
the names, the ocular trachoma lineage commonly infects eye mucosa while urogenital 
linages most commonly infect the genital epithelia. Lymphogranuloma venereum (LGV) 
is a disseminating biovar that thrives within the lymphatic niche. Trachoma biovars are 
subdivided into fifteen serovars based on ompA antigenic variation encoding the major 
outer membrane protein (MOMP).  Loosely, serovars A, B, Ba, and C serve as the 
causative agent of Trachoma, the leading cause of infectious blindness throughout the 
world. Serovars D-K are commonly associated with sexually transmitted infection. While 
L1, L2, L3 are the three main LGV serovars, the newly identified L2b serotype has 
emerged as the causative agent of the current European and North America epidemic 
[54].  
 
 
Ocular Chlamydia trachomatis  
 
The earliest documented historical accounts of chlamydial infection detail 
trachoma, a contagious disease of the conjunctiva, the outside covering of the eye, and 
cornea caused by Chlamydia trachomatis. While trachoma rarely occurs in western 
societies, ocular serovars of C. trachomatis are epidemic in parts of Africa, Asia, South 
America, Australia, and the Middle East making it the world’s leading cause of 
preventable infectious blindness.  
 
Active infection, a self-limiting inflammation of the conjunctiva, is primarily seen 
in children and is transmitted by direct contact with mucosal secretions, poor sanitation, 
inanimate objects such as towels and clothing that have infected secretions on them, and 
natural vectors such as flies (Reviewed by [55] [56]). Recurrent infection, which is 
common in developing countries, leads to the development of scarred tissue and, 
eventually, trichiasis, inversion of the eyelid. Inwardly turned eyelashes cause physical 
damage to the cornea. This results in the blindness seen primarily in endemic adult 
populations. The World Health Organization endeavors to eliminate trachoma by the year 
2020 with the implementation of the S.A.F.E. campaign which includes surgery, 
antibiotics, facial cleanliness, and environmental improvements [57] [58]. 
 
 
Genital Chlamydia trachomatis  
 
Sexually transmitted diseases are hidden epidemics of tremendous health and 
economic consequence in the United States…the scope, impact and consequences of 
STDs are under recognized by the public and health care professionals. 
–Institute of Medicine, 1997 
 
Sexually transmitted Chlamydia trachomatis has a significant impact on human 
health given its adverse effects on reproduction. The World Health Organization 
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estimates that ninety million cases of chlamydial infection occur worldwide each year 
and an estimated four million cases are reported annually in the United States. Many 
believe these estimates are much lower than the actual incidence due to the fact that 
infection is largely asymptomatic. While individuals who are infected may not experience 
symptoms, it is important to note that they are still at risk of developing long term 
sequelae.  
 
In men, C. trachomatis primarily infects the urethra making it the most common 
cause of non-gonococcal urethritis.  In some instances, the infection spreads from the 
urethra to the epididymis resulting in epididymitis, a condition primarily associated with 
sexually active males under the age of thirty-five.  Infection may also result in Reiter’s 
Syndrome in male and female populations.  Whether or not Chlamydia infection plays a 
direct role in male infertility is still controversial despite the fact that chlamydial DNA 
can be recovered from a substantial number of male partners in infertile couples [59] [60] 
and has been recovered attached to spermatozoa from the peritoneal fluid of women with 
salpingitis [61]. 
 
Genital serovars of chlamydiae are of particular importance to women due to the 
irreversible reproductive sequelae that may result post infection. Infection of the cervix 
can ascend causing endometritis, inflammation of the endometrium, and salpingitis, 
inflammation of the fallopian tubes. Untreated C. trachomatis infection has been linked 
to chronic complications such as Pelvic Inflammatory Disease (PID), involuntary 
infertility and ectopic pregnancy. Moreover, chlamydial infection increases the risk of 
contracting human immunodeficiency virus (HIV) and has been implicated in the 
development of human papilloma virus (HPV)-induced cervical neoplasia [62] [63]. 
Although rare, C. trachomatis-induced salpingitis spreading beyond the upper genital 
tract into the peritoneum has been documented. The resulting peritonitis and perihepatitis 
is called Fitz-Hugh-Curtis Syndrome and may be accompanied by upper quadrant 
abdominal pain and the development of adhesions that resemble the strings of a violin 
[64] [65]. 
 
 
Mouse Model of Genital Infection 
Life is hard for insects. And don’t think mice are having any fun either. 
–Woody Allen 
 
Humans are not the only hosts in which chlamydiae can establish an infection and 
cause disease. Guinea pigs, turkeys, sheep, and higher order primates have been used to 
study chlamydiae-associated disease but an extensive amount of data has been extracted 
from mouse models. Mice infected with either C. muridarum or human biovars of C. 
trachomatis are most frequently used as models of chlamydial genital infection due to the 
ease of reproducibility afforded by inbred strains, commercial ability of reagents, and 
genetically engineered animals that allow for immunological interrogation [66]. 
 
While nonhuman primate [67] [68] [69] and guinea pig [70] [71] models of 
infection were established, Barron and colleagues [72] developed a novel system in 
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which researchers intravaginally infected mice with Chlamydia muridarum, previously 
known as C. trachomatis mouse pneumonitis strain or MoPn, in 1981.  In the Barron 
study, chlamydial inclusions were identified by examining Giemsa stained vaginal smear 
preparations and chlamydiae-specific immunofluorescent cervical scrapings and 
epithelial tissue.  These findings were significant because they identified a convenient 
model using a natural mouse pathogen that induced pathologies remarkable similar to 
those observed in humans infected with C. trachomatis serovar D [73].  
 
Mouse models of chlamydial infection have been used to evaluate the role a 
host’s genetic background may play in chlamydiae infection resistance and Chlamydia-
associated outcomes. De la Maza and colleagues intravaginally infected mice with 
varying H-2 complexes to determine its effect on chlamydial-related infertility [74].  The 
H-2 complex defines the major histocompatibility complex (MHC) in mice and is 
homologous to HLA in humans.  Six weeks after challenge BALB/c, C57BL/6, and C3H 
mice were mated with male breeders and the embryos were counted.  Seventy-five 
percent (N=20) of C57BL/6 mice became pregnant and had a mean of 4.5 embryos per 
mouse.  Forty percent (N=20) of BALB/c mice became pregnant and had a mean score of 
1.5 embryos per mouse. Thirty percent (N=20) of C3H animals became pregnant and had 
a mean score of 1.7 embryos per mouse.  From these studies the researchers concluded 
that the genetic makeup of the host modulates the degree of chlamydial-induced 
infertility.  In 1997, Darville et al expanded the study by comparing C3H/HeN mice with 
C57BL/6 mice using varying strains of Chlamydia [75].  When intravaginally infected 
with C. trachomatis, serovar E or C. muridarum, C3H mice had an increased incidence of 
hydrosalpinx, increased chlamydial shedding, and prolonged infection course when 
compared to C57BL/6 animals. This suggested that genetic factors played a role in 
chlamydial resistance and that the murine model could be used to understand the 
mechanisms responsible for resistance variability in the human population.  
 
Advances in human genetics, such as the human genome project, have 
revolutionized our understanding of the host’s role in human health and disease by 
allowing for inter- and intra-species genetic comparisons [76] [77]. Indeed, whole 
genome association studies would allow researchers to interrogate genes and their 
associated disease phenotypes relatively quickly when compared to the previous method 
of “knocking out” genes in in vivo models and looking for changes in the initially 
observed response. As one would expect, identifying conserved genetic sequences across 
diverse species would require vast amounts of genetic information. This requirement 
grants the mouse model a significant advantage over other animal models given the fact 
that genetic sequences and many gene function relationships have been identified and are 
readily available using informatics tools like the Mouse Genome Database 
(http://www.informatics.jax.org/). 
 
Although chlamydial comparative studies are still in their infancy, high-
throughput genomic analyses have the potential to transform how we currently identify 
and therapeutically treat those infected.  As proof of principle, Miyairi and colleagues 
recently sought to predict outcomes of systemic chlamydial infection using recombinant 
inbred mice (BXD) and computational modeling [78]. Infection of parental strains, 
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C57BL/6 and DBA/2J, an extensive panel of B (C57BL/6) x D (DBA/2J) mice, in 
conjunction with gene mapping and computational Bayesian network modeling were 
used to define underlying pathways contributing to variations in disease severity. The 
researchers validated predictions that Ctrq3 or polymorphisms in immunological relevant 
GTPases conferred resistance in B6 dominant genetic backgrounds, whereas, 
susceptibility was heightened in D2 dominant backgrounds as a function of neutrophilic 
influx modulation. While there are no homologs of interferon-inducible p47 GTPases in 
humans, Miyairi’s findings implicate neutrophils as a tentative therapeutic target, validate 
computational chlamydiae-related modeling as a way of predicting disease outcomes, and 
highlight recombinant inbred strains as a way of elucidating previously unknown host-
derived pathways contributing to disease.  
 
 
Murine Genital Tract Pathology  
 
C. muridarum, although originally isolated from the murine respiratory tract [79] 
[80], closely mimicked human sexually transmitted chlamydiae disease when used to 
infect the genital tracts of mice. In 1983, Swenson and colleagues reported Chlamydia-
induced genital pathology mirrored that seen in human populations [81].  In these 
experiments mice were inoculated with C. muridarum in the ovarian bursa, a thin 
membrane that encapsulates the ovary and separates it from the interperitoneal cavity. 
Hydrosalpinx, blockage of the fallopian tube(s) with serous fluid, was observed in mice 
between 25-30 days post infection.  Salpingitis and hydrosalpinx formation have been 
linked to involuntary infertility in human female populations by irreversible scarring in 
the reproductive system and similar outcomes were demonstrated in the model. Although 
the natural route of infection was not used in this study, it validated that the mouse model 
could be used to explore mechanisms associated with the development and severity of 
chlamydiae-induced upper tract complications. Since, several studies, including those 
outlined in this body of work, have demonstrated vaginal inoculation of the mouse results 
in reproducible upper genital tract pathology. 
 
 
Murine Model Limitations 
 
Although the murine model has been advantageous, there are some caveats.  For 
instance, there is great variability in chlamydiae strains, innoculum doses used, and the 
inbred strain used. The efficiency of infection using human strains of C. trachomatis is 
significantly lessened when compared to the strain isolated from the murine respiratory 
tract, C. muridarum [82].  As a result, investigators commonly use higher doses of 
Chlamydia trachomatis to establish murine infections. Inoculating doses have also been a 
point of debate in the chlamydial field. In 2004, Maxion and colleagues evaluated 
differences in BALB/c cell infiltration and pathology formation as a result of innoculum 
doses ranging from 104 to 107 inclusion-forming units (IFUs). They found that dose 
variation altered immune cell representation in the genital tract noting increases in PMN 
and DC infiltrates in the lower genital tract as chlamydial dose increased [83]. Carey et al 
investigated the effects of inoculum dose on pathology development in BALB/c female 
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mice [84]. They concluded higher doses of Chlamydia muridarum lead to greater oviduct 
infection.  
 
Lastly, and perhaps the most relevant argument, is that C. trachomatis is 
transmitted by oral, vaginal, and anal sexual contact with an infected individual. The 
likelihood of large amounts of infectious organisms being transmitted by the routes 
mentioned is low. In support of this argument, the infectious chlamydial load in humans 
is low with a median IFU of 72 from male-derived urethral swabs and 450 IFU from 
cervical swabs taken from women [85]. Collectively, these studies underscore the need to 
standardize infection parameters in chlamydial models across the board to reflect the 
likely transmission inoculums seen in human scenarios of infection. 
 
Another caveat of the mouse model is the five day estrous cycle. The frequency of 
epithelial uterine sloughing proved to be a problem in establishing chlamydial infection 
in mice because the target population (epithelial cells) was turning over prior to the 
completion of the chlamydial developmental cycle. Tuffery et al performed experiments 
that showed the female genital tract epithelium could be stabilized by subcutaneously 
injecting progesterone one to two weeks prior to intravaginal infection (Tuffrey, and 
Taylor-Robinson, 1981). Hormone treatment stabilized murine menses and enhanced 
chlamydiae genital infection by preventing the normal renewal of genital epithelium. As 
a result, the mouse model can be used to study the natural course of infection and 
chlamydiae-induced pathology with increased reproducibility. Currently, the use of 
progesterone in animal models is debated because sex hormones have been shown to 
affect susceptibility to a number of sexually transmitted infections in human and animal 
studies [86] [87] [88]. 
 
Another concern is the availability of a persistent murine model.  In human 
female populations, persistent infections defined by chronic asymptomatic chlamydial 
genital tract infections, may give way to the development of reproductive complications 
such as PID, chronic abdominal pain, and tubal infertility. As mentioned previously, in 
vitro persistent states have been induced by environmental stresses such as the interferon 
gamma inducible tryptophan decyclizing enzyme 2, 3-indoleamine dioxygenase, iron 
depletion, and by treatment with penicillin.  In efforts to reproduce persistence in vivo, 
Ramsey et al used iNOS knockout mice [89]. When NOS2-/- mice were infected with C. 
muridarum, they exhibited higher rates of upper genital tract sequelae but culture-based 
resolution was comparable to that observed in wild-type mice. In 1997, Cotter et al 
intravaginally infected wild-type immunocompetent mice and were able to reactivate 
chlamydiae shedding after initial clearance, evidenced by the inability to recover viable 
organisms  from the vaginal vault, with the immunosuppressive drug cyclophosphamide 
[90].  While these studies illustrate persistence in the mouse, the mouse model may not 
be a useful tool for exploring mechanisms of persistent infection because it difficult to get 
reactivation. Further investigation for a suitable animal model is warranted given the lack 
of conclusive evidence for persistent infection in the human population. 
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Immunological Response to Genital Infection 
 Before discussing the host immune response to sexually transmitted chlamydial 
infection, it is important to note key distinctions of the female genital mucosa when 
compared to other mucosal sites of the body. The reproductive environment is unique in 
that it must exhibit a certain level of tolerance for commensal flora that colonize the 
lower genital tract and withstand the presence of an immunologically foreign fetus in the 
uterus during pregnancy, all the while maintaining its ability to mount a response to 
pathogenic organisms.  In addition, the genital environment differs from other mucosal 
sites like the proximal intestinal system in that many of its effector functions, including 
immunological properties, are hormonally regulated [91].  These distinctions and the lack 
of local concentrations of lymphoid tissue such as the gut-associated lymphoid tissue 
(GALT) component Peyer’s Patches in the intestine or bronchular-associated lymphoid 
tissue (BALT) in the lung contribute to the complexity of chlamydiae infection in the 
genital tract.  
 
 
Intracellular Immune Response Overview 
 After “self verses non-self” discrimination, the host orchestrates appropriate 
immunological responses based on the niche in which pathogens thrive [92]. Bacteria 
such as Mycobacterium tuberculosis[93] [94], species associated with the genus 
Rickettsia [95] [96], chlamydial species [82] [97] [98] [99] [100] [101], and viruses like 
HIV [102] [103] and influenza [104] are hallmark intracellular pathogens that require 
specialized approaches to achieve clearance. Antigen-presenting cells (APCs) and T-cells 
are crucial to intracellular pathogen elimination. For instance, pattern recognition 
receptors (PRRs) associated with APCs like dendritic cells or macrophages recognize 
pathogen-associated molecular patterns (PAMPs) which, in turn, initiate antimicrobial 
compounds such as interferon-gamma, tumor necrosis factor-alpha, and interleukin-two 
[105].  These cytokines assist in the activation of other APCs and push naïve T-cells 
(Th0) toward an appropriate TH1 pathogen-specific linage. This cascade culminates in B-
cell activation and the development of plasma cells, antibody-producing B-cells that 
ready the host for subsequent encounters.   
 
 
Chlamydia Innate Response  
 
 Induction of the innate immune response is central to mounting an effective attack 
against chlmaydial genital pathogens. The process begins with the recognition of 
pathogen associated molecular patterns (PAMPS) by Pattern Recognition Receptors 
(PRRs) of Antigen Presenting Cells (APCs) or host cell membranes. Various chlamydiae 
components or the entire organism may serve as ligands for toll-like receptors (TLRs), a 
membrane bound family of PRRs. For example, chlamydiae-derived lipopeptide was 
shown to stimulate TLRs 2, 1, and 6 in macrophages [106]. Although less stimulatory 
than E. coli lipopolysaccride (LPS), chlamydial LPS may serve as a ligand for TLR4 
[107] and to a lesser extent TLR2 [108]. Moreover, whole organism was used to 
determine differences in chlamydiae-induced oviduct pathology after discriminatory 
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stimulation of TLRs 2 and 4 [109]. Stimulation of TLRs give way to activation of the 
NF-K B pathway which, in turn, results in production of pro-inflammatory cytokines and 
chemokines.  
 
Almost immediately after infection, a cascade of proinflammatory cytokines are 
secreted by the target epithelium. This was first reported by Rasmussen and colleagues in 
1997 [110].  Using the in vitro HeLa 229 epithelial cell line, these studies showed that 
interleukin-8, growth-related oncogene- alpha (GRO-alpha), neutrophil-derived 
granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-6, and 
interleukin-1alpha were secreted following infection.  Experiments using mouse derived 
oviduct epithelial cells performed by Johnson et al showed that proinflammatory 
cytokines and chemokines like tumor necrosis factor alpha, GM-CSF, interleukin-6, MIP-
2, KC, MCP-1 and MCP-5 were produced following C. muridarum infection [111].  The 
secretion of these effector molecules lead to the massive influx of innate immune cells.  
Darville and colleagues, by flow cytometry, and Morrison and Morrison, by in situ 
immmunohistochemistry, characterized the primary infiltrate and found that monocytes, 
natural killer cells, and neutrophils were prevalent in these cell populations [75] [112]. 
The newly recruited cells expanded the repertoire of effector molecules being produced 
and, depending on the cytokines and chemokines released, recruited pathogen-specific 
lymphocytes to the site of infection.  
 
 
Chlamydia Adaptive Response  
 
 Effective host responses require the induction of, both, the innate and acquired 
arms of the immune system. Indeed, resident and recruited innate immune cells such as 
neutrophils and professional antigen presenting cells such as macrophages and dendritic 
cells begin producing tumor necrosis factor-alpha, interleukin-12, and interferon-gamma. 
This stimulates naïve T cells toward CD4 T-helper 1 lineages which are necessary for 
chlamydial clearance in the genital tract. Studies in interferon gamma [113] and 
interferon gamma receptor knockout mice [114] illustrate a prominent role for the 
cytokine in the resolution of primary chlamydial infection. Rank and colleagues first 
demonstrated an important role for CD4 T cells in the genital tract by vaginally infecting 
athymic nude mice [115].  Nude animals had an active infection evidenced by chlamydial 
shedding for more than 200 days post infection, whereas animals with intact T cell 
populations resolved infection within 21 days. Landers et al reinforced this finding in 
1991 when they used CD4 antigen specific anti-L2T4 antibodies to deplete CD4 in mice 
vaginally infected with C. muridarum [116].  These depletion studies resulted in 
increased vaginally shedding of Chlamydia and an increased number of organisms 
recovered from the oviduct.  Su et al later transferred CD4 and CD8-enriched spleen cells 
from immune mice to naïve mice and found that adoptive transfer of CD4 lymphocytes 
conferred immunity in C. muridarum genital tract infection [117].  Kelly and colleagues 
published work illustrating that CD4+ cells were abundantly recruited to the genital tract 
following intravaginal infection due to interaction between CD4+ cell home receptor 
alpha-4-beta-7 and adhension molecules, ICAM-1, VCAM-1, and  MadCAM-1 [118] 
[119]. Most recently, Gondek and colleagues reported that CD4+ T cells were necessary 
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and sufficient to clear genital tract infection [120].  Using transcervical inoculation, a 
method that directly infects the uterine lining of mice, the researchers demonstrated C. 
trachomatis, LGV and C. muridarum infected mice are protected from infection and 
reinfection when treated with pathogen-specific CD4+ lymphocytes.  Furthermore, when 
animals were treated with anti-CD4 antibody, Chlamydia 16S DNA levels where 
comparable to those observed in naïve mice. Collectively, these studies demonstrate the 
importance of T helper 1 type cytokines and CD4 T cells in the resolution and protection 
of chlamydial-induced genital infection.  
 
 The humoral response has also been implicated in chlamydial immunity. Plasma 
cells, commonly known as antibody producing B cells, are thought to play a leading role 
in protecting against reinfection, while playing a secondary role to CD4-mediated 
resolution of primary infection [99].  One mechanism by which B cells may control 
subsequent infection is by antibody driven neutralization, which is plausible given the 
biphasic developmental cycle of chlamydiae.  Data from Peeling et al using serum from 
guinea pigs to neutralize C. trachomatis with UM-4, a strain specific monoclonal 
antibody in an in vitro neutralization assay support this theory [121].  Furthermore, 
Morrison and colleagues showed that B-cell deficient mice, when depleted of CD4+ T 
cells during secondary infection, where unable to clear infection [98] [99].  Although the 
experiments by Morrison et al did not rule out the feasibility of direct neutralization, they 
implicated a more collaborative mechanism between CD4 lymphocytes and plasma cells, 
perhaps by the enhancement of antigen presentation during recurrent infection episodes. 
Although the exact mechanism remains unclear, antibody, particularly IgG given it is the 
predominant antibody produced in the genital mucosa, is thought to play a collaborative 
role in chlamydial immunity.  
 
 
Vaccination  
 
The prevention of disease today is one of the most important factors in the line of human 
endeavor. 
–Charles H. Mayo, M.D. 
 
 The immune response is the host’s natural defense mechanism to foreign antigens 
but the system can be manipulated to respond to foreign antigens quicker and more 
efficiently than if it were the first encounter.  The previously mentioned form of 
manipulation serves as the basis for vaccination or, what some refer to as immunization.  
 
Although current anti-chlamydial therapies effectively clear the organism from 
the lower genital tract, they do not address the potential consequences of reinfection. 
Batteiger and colleagues reported that almost one third of previously infected individuals 
are reinfected with the same serovar due to sexual interaction with the same sexual 
partner [122], potentially increasing the likelihood of irreversible tissue damage. One 
way of addressing reoccurring infection is through the development of an effective and, 
most importantly, safe vaccine.  
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 Perhaps the most well-known C. trachomatis vaccination studies were the 
trachoma human trials performed in the 1960’s [123] [124]. During these trials children 
were intramuscularly vaccinated with formalin-fixed whole organisms and traced for 
three years. Unfortunately, a portion of those immunized developed severe disease upon 
exposure to chlamydiae while others developed partial, serovar-specific immunity when 
compared to unvaccinated controls. Since then, vaccination studies have been exclusively 
performed in animal models and frequently exploit components of chlamydiae for 
vaccination.   
 
 First purified by Caldwell and colleagues [125], the major outer membrane 
protein (MOMP) has been the focal point of chlamydiae subunit vaccination studies for 
the past thirty years. Recently reviewed by Farris and Morrison, native or recombinant 
protein, DNA, plasmid, and outer membrane complexed MOMP have been the most 
frequently studied MOMP-derived antigens [126].  At best, these studies have only 
elicited partial immunity by either failing to reduce bacterial burden, failing to protect 
animals from reinfection, and/or failing to protect against sequelae formation.  
Interestingly, recombinant vault nanoparticle delivery of MOMP immunogens has 
renewed hope in MOMP’s potential as an effective vaccine candidate.  Intranasal 
immunization with rMOMP nanoparticles results in a T-helper 1 driven immune response 
and significantly reduces chlamydial vaginal shedding when compared to animals 
immunized with live C. muridarum [127]. 
 
 Additional antigens have been identified based, mainly, on human seroactivity.  
Some of these include chlamydial protease-like activity factor (CPAF), other outer 
membrane proteins such as OmcB and Pmps, porin protein B (PorB), and the type III 
secretion protein, Tarp.  Of the previously mentioned chlamydial components, CPAF was 
thought to have the most promise. Intranasal immunization with recombinant CPAF 
(rCPAF) plus interleukin-12 reduced bacterial shedding and sequelae formation in 
BALB/c intravaginally challenged with C. muridarum [128]. In addition, rCPAF and 
Cpg-1826 was used to intranasally immunize BALB/c mice prior to multiple rounds of C. 
muridarum intravaginal challenge [129]. rCPAF plus CpG vaccination resulted in a 
significantly greater number of pregnancies when compared to mock immunized controls 
indicating protection post primary and secondary exposures to genital chlamydial 
infection.  In 2012, Chen et al called into question the entire body of work done using 
CPAF and its proposed substrates after reporting CPAF lost its ability to cleave or 
degrade 11 of the 16 previously reported host proteins when a CPAF- specific inhibitor 
was used prior to cell lysis [130]. These results suggest that the proteolysis activity 
observed in all previous CPAF studies was likely due to the way in which the 
preparations were prepared and discredit, at least for now, the idea that CPAF protease 
activity is a virulence factor important in chlamydial pathogenesis.  
 
 
Control Measures 
Chlamydia trachomatis infection is the most commonly reported sexually 
transmitted disease in the United States and a significant threat to public health world-
wide. Chlamydia control programs were implemented to alleviate the public health 
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burden of chlamydial infection by improving detection mechanisms, shortening the 
duration of infection, and tracking source-associated sexual networks [131]. These 
programs ushered in an initial lag phase denoted by a decline in chlamydial cases. 
However, over the last two decades, case notifications of Chlamydia-associated infection 
have steadily increased and, in many countries, exceed rates recorded prior to the 
implementation of intervention strategies [132] [133] [134]. Norway, Finland, Sweden, 
and Canada have documented similar trends with an initial decline following the 
introduction of Chlamydia control programs [132] [135] [136] [137]. In recent years, 
these countries have witnessed chlamydial rates exceeding those recorded prior to the 
establishment of surveillance systems. Given the magnitude and scope of current 
epidemiological trends, researchers and policy makers alike are interested in pinpointing 
the causal agent(s) for increased chlamydial case notifications.  
 
 
Sexually Transmitted Chlamydia Epidemiology  
 
 The insidious nature of Chlamydia trachomatis infection has made it the world’s 
most common cause of curable sexually transmitted disease. In 2010, over a million cases 
(1,307,893) of chlamydial genital tract infection were reported to the Centers for Disease 
Control and Prevention from fifty states and the District of Columbia [63].  This was the 
largest number of cases reported to the CDC for any reportable condition with a case rate 
of 426.0 per 100,000 people, representing a 5.1% increase in reported cases over the 
previous year. Although these rates are staggering, the actual number is more than likely 
higher than that reported seeing as many cases remain undiagnosed.  
 
 Gender disparities have consistently been reported among individuals infected 
with sexually transmitted C. trachomatis. According to the National Sexually Transmitted 
Disease Surveillance Report 2010, women bear a heavier Chlamydia burden than men 
with reported rates two and half times more than their male counterparts despite the fact 
that Quinn and colleagues reported a nearly identical frequency of transmission among 
494 male and female sexually transmitted disease clinic patients [138]. This discrepancy 
may be attributed to the fact that women are more likely than men to be screened for 
chlamydial infection [139]. However, the switch from urethral swabbing to urine-based 
non-invasive nucleic acid amplification testing as the main detection method may result 
in more men opting to get tested [140] [141]. This is supported, at least in part, by the 
36% increase in chlamydiae case notification since the year 2006. A 19.5% increase was 
observed in the female population between 2006 and 2010, indicating the increase in 
male reporting was not solely because of an increase in population-based chlamydiae 
prevalence [63].  
 
 Age has been implicated as a risk factor for urogenital chlamydial infection [142] 
[143] [144] [145] [146] [147] [148].  The highest notification rates correspond to sexually 
active female adolescents between the ages of 15-19. The second highest rate among 
females is young adults between the ages of 20-24. Age-specific rates among males are 
higher among 20-24 year olds with 1,187 cases per 100,000 people reported in the year 
2010. These numbers are particularly troubling considering chronic chlamydial 
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complications have been linked to infertility in both genders and the age groups greatest 
affected represent peak reproductive years [63].  
  
Significant ethnic and racial disparities exist among reported sexually transmitted 
infections, specifically Chlamydia cases. For instance, African-Americans only represent 
14% of the national demographic, but they account for approximately half of all reported 
syphilis and chlamydiae cases and 75% of all reported gonorrhea infections [63]. With an 
incidence rate 1,167.5 per 100,000 persons, African-American chlamydial rates are eight 
times higher than white Americans.  American Indian/Alaska Natives chlamydial rates 
are 4.3 times higher than white Americans while Hispanic American chlamydial rates are 
2.7 times greater than those reported among Caucasian-Americans. While it would be 
easy for researchers and epidemiologists to dismiss these health inequalities based on the 
idea that these communities are more susceptible to infection and/or are more likely to 
participate in risky behaviors, the reasons are more complex [149]. While individual 
behaviors can influence health, surveillance trends are, in large part, influenced by 
cultural, economical, environmental, educational, and social factors [150] [151] [152].  
For instance, in a study conducted by Kaplan and colleagues in 77 different Chicago 
communities, sexually transmitted infections were higher in neighborhoods that had high 
poverty rates, high unemployment rates, and a low percentage of high school graduates 
[153].  In a cross-sectional analysis of over 12,000 young adults, Nguyen et al concluded 
that geographical location and economic status were factors associated with chlamydial 
reporting with study participants living in the southern region and no functional income 
being more likely to report chlamydiae infection [154].  While the studies citied highlight 
findings seen in relatively small participant groups, they are representative of health 
determinants influencing national surveillance profiles. 
 
 
Hypotheses for Rebounding Chlamydia Rates  
 
 Seven hypotheses were put forth to explain this phenomena and were published 
by Rekart and Brunham [133] and are adapted in Table 1-2.  Hypotheses one through 
four relate to the use of nucleic acid amplification testing for detecting genital infection 
with chlamydiae.  Hypothesis one speaks to an increased probability of “false positive” 
tests because of a loss of specificity in detection methods.   Watson and colleagues 
performed a meta-analysis including the following diagnostic methods for urogenital 
chlamydia: nucleic acid amplification testing (NAAT), gene probe, enzyme immunoassay 
(EIA), direct immunofluorescence (DFA), and cell culture [141].  The study concluded 
that NAAT testing was the best option for massive screening programs because the 
results were comparable to those observed using the “gold standard”, cell culture, and 
urine samples did not constitute a gender bias. Men and women would be willing to 
undergo screening using this non-invasive technique.  
 
Hypotheses two through four argue increased sensitivity, improved screening 
amongst high-risk populations, and greater screening among the male population are the 
basis for surveillance data trends.  In 2006, Burckhardt et al assessed the impact of 
changing from culture-based chlamydial detection to nucleic acid amplification testing in   
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Table 1-2. Increased chlamydial rate hypotheses.  
 
Hypothesis 
Number 
Hypothesis Description 
H1 False positive increase due to lower specificity of NAAT methods 
compared to culture methods 
 
H2 Increase in case detection due to increased sensitivity of NAAT testing 
compared to non-NAAT testing 
 
H3 Higher testing rates among men due to non-invasive NAT urine-based 
testing 
 
H4 Targeted screening of high-risk populations and NAAT self-collected 
sampling among female population(s) 
 
H5 Development of antibiotic resistance 
 
H6 Increase in unsafe sexual behaviors 
 
H7 Chlamydial arrested immunity 
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a genitourinary medicine clinic cohort [155]. Although an initial increase in positive 
testing occurred in the two and half years immediately following the implementation of 
NAAT testing, positive test percentages returned to those observed prior to the detection 
method change. The researchers concluded that the upturn of chlamydial incidence was 
not exclusively due to the improvement of detection methods.   
Hypothesis five suggests antimicrobial resistance is responsible for the 
rebounding rates. Indeed, antibiotic resistance is a serious issue, particularly for 
individuals infected with syphilis and/or gonorrhea [156] [157] [133] [158], two major 
sexually transmitted infections.  Although tetracycline resistance has been documented in 
chlamydiae serovars that infect livestock [159], resistance among human isolates are 
rarely observed. 
 
Hypothesis six implicates the safe sex practices, or lack thereof, as a potential 
cause. Undoubtedly, the behavioral choices made by individuals influence population-
based surveillance data.  Perhaps the ideal example is that of HIV/AIDS. After the initial 
recognition of HIV in the early 1980’s, huge awareness campaigns were implemented 
that led to a decline in STI transmission across the board [160] [161].  After effective 
treatment was introduced and the general population no longer viewed HIV/AIDS as a 
“death sentence”, STI incidence rates rebounded. This demonstrates that effect of human 
behavior on modulating infection cases and confirms the likelihood of current trends 
being a result of several factors.   
 
The final hypothesis is the arrested immunity hypothesis. Although it is important 
to remember that none of the previously mentioned postulates are likely to be mutually 
exclusive, the arrested immunity hypothesis is the cornerstone of my dissertation research 
and the primary theme hereafter.  
 
 
Arrested Immunity Hypothesis  
 
The arrested immunity hypothesis asserts that prompt treatment of genital tract 
infection is coupled with a reduction in naturally acquired immunity, resulting in 
increased incidence and prevalence of chlamydial infection [132]. Interference with the 
development of host immunity to chlamydiae genital infection has been shown using the 
urogenital murine model by the Caldwell research group [162]. Su and colleagues treated 
C57BL/10 female mice with doxycycline at different timepoints postinfection.  No IgG 
antibody was detected in sera from animals that received treatment at day zero, the onset 
of infection. This demonstrated the effects of early treatment on the development of anti-
chlamydial immune responses.   
 
Brunham et al applied the Cox proportional hazards model to evaluate the effects 
of antibiotic treatment on the development of population-based immunity [163]. The Cox 
model is a statistical survival model developed by Sir David R. Cox that relates the time 
between an “event” occurring to one or more covariates that make also occur within that 
time frame.  The Brunham model is hinged on findings by Molano and colleagues [164] 
suggesting immunity in human populations may take years to develop. These findings, 
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when considered with the early treatment component of control programs, suggest that 
human hosts don’t develop an adequate immunological response to chlamydiae due to the 
truncated exposure time with chlamydial antigen(s) in the genital tract. Using the Cox 
model, Brunham’s groups concluded that early treatment renders the general population 
more susceptible to reinfection. 
 
 
Dissertation Rationale 
Despite the implementation of wide-spread control initiatives, sexually 
transmitted Chlamydia rates continue to rise and are coupled with a decline in 
chlamydiae-associated chronic complications such as PID, ectopic pregnancy, and 
involuntary infertility [131].  Several rebounding hypotheses have been put forth to 
explain current surveillance trends and, optimally, humans studies would provide the 
most insight as to why intensive screening and treatment strategies are, seemingly, 
ineffective. For obvious reasons, these studies are impractical given the ethical concerns 
surrounding trials undertaken with the potential of chlamydial-induced upper genital tract 
complications. Taking into account current therapeutic intervention, immune arrest and 
infection history, we used the chlamydiae urogenital mouse model to determine the 
effects of antibiotic treatment on duration of infection, immunological parameters and, 
most importantly, chlamydial-induced upper tract complications in primary and 
reoccurring cycles of infection. Moreover, we documented the effects of host factors, 
such as age and genetic make-up, and immunization on the development of severe 
chlamydial-induced genital tract disease.  
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CHAPTER 2.    ARRESTED IMMUNITY: IMPACT OF EARLY TREATMENT 
ON UPPER GENITAL TRACT SEQUELAE 
 
 
Introduction 
Sexually transmitted Chlamydia trachomatis is the most commonly reported 
notifiable infection in the United States [147]. Although up to 75% of women and 50% of 
men with lower tract chlamydial infections are asymptomatic [165] [166] [167], the 
potential to develop genital tract sequelae remains unchanged when compared to 
individuals that experience symptoms such as postcoital bleeding, fever, abdominal pain, 
and mucopurulent vaginal discharge [168]. This is of particular concern given the 
reported rate of chlamydial infection among women is over two and half times greater 
than the reported rates for men [147] and C. trachomatis infection can ascend into the 
female upper genital tract causing long term reproductive complications such as ectopic 
pregnancy, involuntary infertility, miscarriage, and increased risk of coinfection and 
transmission of other pathogenic agents [169] [170] [171] [172]. As a result, in the 
absence of a protective chlamydial vaccine, Chlamydia prevention efforts mainly focus 
on increasing the rate of screening and treating infected individuals [134] [170] [173]. 
 
While current antibiotic regimens are highly effective in clearing the organism 
during uncomplicated lower genital tract infection [174] [175], it has been reported that 
doxycycline treatment prevents the development of host immune responses in a murine 
model of chlamydial genital infection [162]. Furthermore, Brunham and Rekart 
hypothesized that populations were susceptible to reinfection due to a shortened duration 
of C. trachomatis encounters which may limit natural immunity [132] [133]. Indeed, 
repeated chlamydial exposure has been identified as a risk factor for worse disease in 
animal and human studies when compared to reference groups that have only been 
exposed once or are considered low-risk sexually transmitted disease populations [176] 
[177] [178]. Among a high- risk population of sex workers, reoccurring C. trachomatis 
infection was associated with Pelvic Inflammatory Disease [179]. Similarly, in a 
retrospective study of 11,000 Wisconsin women, ≥3 positive chlamydial tests increased 
the chances of Pelvic Inflammatory Disease diagnosis by a factor of six [177].  Although 
these studies indicate an increased risk for severe disease following multiple positive 
Chlamydia tests, they fail to distinguish between prolonged exposure and reinfection, or 
the role antibiotic intervention played, if any, in the development of disease. This is 
further complicated by the initial decline in reported chlamydial infection rates following 
the introduction of screening and treatment control programs which have since rebounded 
to levels comparable or exceeding those observed prior to the implementation of 
intervention strategies.   
 
In this study, we sought to determine if data derived from population surveillance, 
human studies, and in vivo experiments could be recapitulated using the urogenital mouse 
model as a framework to determine how treatment at various time-points throughout the 
course of an active primary infection affects disease outcomes during repeated infection 
cycles. 
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Materials and Methods 
 
Mice  
 
 7 to 8 week old C57BL/6J mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME) and maintained at our facility, which is fully accredited by the 
Association for Accreditation and Assessment of Laboratory Animal Care International.  
The Animal Care and Use Committee at the University of Tennessee Health Science 
Center (Memphis, TN) approved all animal studies.  
 
 
Chlamydia Strain and Titration 
 
The Chlamydia muridarum Weiss strain was propagated in HeLa 229 cells and 
stored at -80oC. Chlamydial titer was evaluated by infecting HeLa 229 cells and counting 
Inclusion Forming Units (IFUs) by fluorescence microscopy as previously described 
[113].  
 
 
Mouse Infection  
 
Mice were subcutaneously treated with 2.5 mg of medroxyprogesterone acetate 
(Sicor or Depo-Provera, Pfizer, New York, NY) in 0.1 mL of PBS at fourteen and seven 
days prior to vaginal infection. Mice were infected by vaginal inoculation with 2 x 103 
IFU of C. muridarum in 10 uL of sucrose phosphate glutamic acid (SPG) buffer.  For 
rechallenge experiments, mice were treated with progesterone and vaginally challenged, 
as previously described, fifty-six days post primary infection unless otherwise specified.  
 
 
Antibiotic Treatment 
 
Mice were treated daily with 0.3 mg of doxycycline hyclate (APP 
Pharmaceuticals, Schaumburg, Il) diluted in distilled, endotoxin-free water (HyClone, 
Logan, Ut) by interperitoneal injection during the primary infection course only. All 
treatment groups received antibiotic for fourteen days consecutively except for 
uninfected, negative control mice treated with progesterone. Treatment groups included 
treatment from 0-14 d, 14-28 d, 28-42 d, 35-49 d, and Untreated-(UN).  
 
 
Bacterial Shedding 
 
Vaginal swabs were taken on interval days throughout infection and collected in 
2-mL microcentrifuge tubes that contained 0.5 mL of SPG (with three 4mm diameter 
round glass beads) and stored at -80oC. Swab samples were thawed and vortexed.  
Infectivity was quantified by inoculating Hela 229 monolayers seeded in 48-well plates 
with swab supernatant fluid.  After 44 h incubation at 37oC in an atmosphere of 5% CO2, 
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plates were washed with PBS-Azide and methanol fixed. Chlamydial inclusions were 
visualized and counted by fluorescence microscopy. 
 
 
Fluorescence-Linked Immunosorbent Assay (FLISA) Antibody Analysis 
 
For total immunoglobulin G (IgG) and IgG isotype studies, HeLa 229 cells were 
seeded in 48-well plates (CoStar, Corning, NY) at a cell number of 105 cells/well 
overnight. HeLa 229 monolayers were infected with C. muridarum at a multiplicity of 
infection (MOI) of two for 2 hours with consistent rocking at 37oC. The innoculum was 
immediately aspirated and plates were incubated in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies, Carlsbad, California) complete containing 2ug/mL of 
cycloheximide for 36 hours at 37oC in an atmosphere of 5% CO2. Following incubation, 
plates were washed 3 times with PBS-Azide and fixed with 500 uL of methanol per well 
for 10 minutes. After fixation, plates were washed 3 times with PBS-Azide and incubated 
at 37oC with a 1:500 dilution of murine sera, pooled based on antibiotic treatment group, 
in PBS/0.1% grade IV ovalbumin/0.05% Tween 20. After incubation, plates were washed 
3 times and incubated with FitC-conjugated rat anti-mouse IgG, IgG1, IgG2a, IgG2b 
(Southern Biotech, Birmingham, AL), FitC-conjugated goat anti-mouse IgG2c, or Alexa 
Fluor ® 488 -conjugated goat anti-mouse IgG3 (Invitrogen by Life Technologies, 
Carlsbad, California) for thirty minutes. Plates were washed 3 times with PBS-Azide and 
fluorescence intensity was immediately read as fluorescent light units (FLUs) at 
sensitivity 70 using a Biotex Synergy 2 Microplate Reader. Results represent the mean of 
triplicate values for each pooled sample group while the solid horizontal bar denotes 
background intensity as measured by normal sera from uninfected untreated animals.  
 
 
Pathology 
 
Immediately following sacrifice, individual mice were grossly examined for 
genital tract pathology abnormalities and photographs were taken.  The uterine horns and 
oviducts were collectively and separately scored based on dilation and visual 
inflammation (reddening and blockage) of the aseptically removed urogenital tissue. 
Scoring for dilation of uterine horn and oviduct tissues was as follows: 0, normal/no 
significant dilation; 1, mild dilation of a single cross-section; 2, one to three dilated cross-
sections; 3, more than three dilated cross-sections; 4, confluent dilation.  Excised tissues 
were methanol fixed and paraffin-embedded. Longitudinal sections were later stained 
with one of the following: hematoxylin and eosin (H&E), NIMP-R14 (neutrophil 
identifying marker), CD68 (macrophage identifying marker), CD4 (T-cell identifying 
marker), and Toluidine Blue (mast cell identifying stain).  
 
 
Organ-Total Body Weight Ratio Analysis 
 
Mice were individually weighed to obtain the total body weight in grams. 
Immediately following sacrifice, the genital tract was aseptically removed and weighed in 
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milligrams. Organ-total body weights were expressed as a function of organ weight 
divided by total body weight to generate weight ratios.  Weight ratios for each animal 
were averaged by corresponding antibiotic treatment group.  
 
 
Statistical Analysis 
 
 Statistical significance of differences between treatment groups was analyzed 
with GraphPad Prsm 4 software (La Jolla, CA) using one-way analysis of variance 
(ANOVA) with post hoc Tukey testing comparing all possible pairs of means unless 
otherwise noted. The strength of linear correlations was determined using Pearson 
product moment correlation coefficient unless otherwise noted. All analyses were 
performed using two-tailed testing at a 95% confidence interval of difference. 
 
 
Results 
 
Kinetics of Genital Tract Infection in Antibiotic-Treated Mice 
 
To evaluate the effect of antibiotic treatment on the duration of chlamydial 
infection, cervicovaginal swabs were collected throughout the primary course of 
infection.  Progesterone treated mice were vaginally infected with 2 x 103 IFU 
chlamydiae, treated with doxycycline and swabbed as described in Materials and 
Methods.  Mice infected but not treated displayed kinetics of an active infection shedding 
3-5 log10 of viable organisms within the first 3 weeks (Figure 2-1). These untreated 
animals were culture negative, indicating a natural resolution of lower genital tract 
infection, by approximately week four. We were unable to recover infectious organisms 
at day four after inoculation in early treated animals, the earliest time point analyzed. 
This suggests that antibiotic treatment prevented intravaginal chlamydial colonization, 
negating the establishment of an active urogenital tract infection. Mice that started 
treatment at an intermediate time point (14-28 d) exhibited a rapid reduction in 
recoverable organisms after the onset of treatment, whereas, groups treated late during 
the infection cycle (treatment initiation at day 28 or 35) paralleled untreated clearance 
rates.  
 
 
Immune Arrest and Pathology Following Primary Infection of Antibiotic-Treated 
Mice  
 
Antibiotic treatment has been shown to prevent the onset of host immune 
responses and the development of upper tract pathology post primary infection [162] 
[180]. To assess whether an immunological response had occurred we measured systemic 
chlamydial specific IgG antibody titers post primary infection by FLISA in addition to 
scoring the severity of disease.  As hypothesized, pathology following primary challenge 
was significantly reduced in early treatment groups when compared to later treatment 
groups or untreated controls (Figure 2-2).  Animals that began treatment at 14 days post   
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Figure 2-1. Shedding of viable C. muridarum following intravaginal challenge. 
 
Note: Solid lines represent various antibiotic treatment groups. Blue: Untreated control, 
Red: (0-14 d), Green: (14-28 d), Purple: (28-42 d), Aqua: (35-49 d). Symbols represent 
the mean inclusion forming units (IFUs) per milliliter recovered at each time point. Error 
bars denote standard deviation (SD) on a log10 scale.  
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Figure 2-2. C57BL/6 pathology severity scores 49 days post-primary C. 
muridarum intravaginal infection. 
 
Note: Solid bars represent the mean severity score for each treatment group. Symbols 
represent individual animals. Differences between treatment groups were observed by 
one-way analysis of variance (ANOVA) with post-hoc analysis using a Tukey-Kramer 
Multiple Comparison test. * denotes p < 0.05 at 95% confidence interval of difference. ** 
denotes p < 0.01 at 95% confidence interval of difference. No difference was observed 
between untreated animals and animals treated at 14-28d, 28-42d, and 35-49d. These data 
are representative of multiple experiments.  
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primary infection displayed reduced disease scores (mean of 1, mild disease) when 
compared to moderately diseased untreated animals and late treatment groups. In 
addition, the severity of upper genital tract complications followed the same trend 
established with the development of chlamydiae-specific immune responses (Figure 2-3). 
In treatment groups where Chlamydia- specific antibody titers were observed as 
determined by FLISA analysis, chlamydiae-related genital pathology was more severe. 
Total anti-chlamydial IgG antibody titer was undetectable in early treated animals and 
was significantly different in comparison to untreated animals and animals treated at 14-
28d, 28-42d, and 35-49d. Anti-chlamydial IgG levels resembling those of untreated 
controls suggested a role for immune-mediated upper tract pathology in the development 
of adverse disease outcomes.  
 
 Given the importance of anti-chlamydial Th1-dominant adaptive responses in the 
resolution of chlamydiae genital infection [181] [182] [183] [184], we evaluated the 
effects of antibiotic intervention on isotype switching as a marker for Th1 verses Th2 
biased responses in a FLISA assay with C. muridarum-infected HeLa 229 cells as 
antigen.  IgG isotypes were undetectable following early treatment but data for untreated 
and late treated animals strongly suggested a Th1 bias, evidenced by IgG2 dominance, 
regardless of the onset of antibiotic intervention (Figure 2-4).  Collectively, these data 
implicate a bias for Th1 immunity irrespective of severe disease development or the 
initiation of anti-chlamydial drug intervention.  
 
 
Disease Severity Following Reinfection in Antibiotic-Treated Mice 
 
 Repeated infections are common in women and early treatment and have been 
postulated to increase reinfection susceptibility on the population level [163] [185] [186]. 
Therefore, it was important to assess whether immune arrest during primary infection 
contributed to disease severity post-secondary infection in our model. As a result, mice 
were rechallenged 56 days after primary vaginal encounter to assess disease severity 
following repeated infection. The animal groups are reflective of the onset of antibiotic 
treatment during primary infection as animals did not receive treatment during the 
secondary infection course. Gross examination of early treatment samples showed 
significant differences in the magnitude and localization of Chlamydia-induced 
pathology. Data presented in (Figure 2-5) show that reinfected animals treated at day 
zero during primary infection had a mean disease severity score of 1.6, indicating mild to 
no disease. Conversely, animals treated at days fourteen, twenty-eight, and thirty-five 
displayed moderate to severe disease, with mean severity scores ranging from 2-3.1. To 
ascertain differences in the localization of disease, we separately scored uterine horn 
(Figure 2-6A) and oviduct (Figure 2-6B) pathology. Early treatment resulted in 
significantly less endometrial disease when compared to untreated controls or animals 
treated at fourteen, twenty-eight, and thirty-five days post primary infection. Gross 
evaluation of the oviduct pathology revealed mild disease irrespective of the onset of 
treatment. 
 
In contrast to human isolates, C. muridarum may result in pathology and   
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Figure 2-3. Total Immunoglobulin G (IgG) antibody response 49 days post-
primary C. muridarum intravaginal infection.  
 
Note: Bars represent mean fluorescent light units (FLUs) for each treatment group. 
Differences between treatment groups were observed by one-way analysis of variance 
(ANOVA) with post-hoc analysis using a Tukey-Kramer Multiple Comparison test. ** 
denotes p = 0.001 at 95% confidence interval of difference. 
  
N
or
m
al
B
uf
fe
r
U
nt
re
at
ed
(0
-1
4)
(1
4-
28
)
(2
8-
42
)
(3
5-
49
)
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000 p=0.001
**
Doxycycline Treatment
M
e
a
n
 F
L
U
28 
 
 
 
Figure 2-4. Immunoglobulin G (IgG) isotype responses 49 days post C. 
muridarum intravaginal infection in mice intraperitoneally treated with doxycycline.  
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Figure 2-5. Incidence and severity of upper genital tract sequelae in antibiotic- 
treated mice 28 days post-secondary infection. 
 
Note: Solid bars represent the mean severity score for each treatment group. Symbols 
represent individual animals. Data depicted here represents trends seen in multiple 
experiments.   
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Figure 2-6. Incidence and severity of uterine horn and oviduct sequelae in 
antibiotic-treated mice 28 days post-secondary infection.  
 
Note: Solid bars represent the mean severity score for each treatment group. Symbols 
represent individual animals. Data depicted here represents trends seen in multiple 
experiments. 
  
31 
infertility after a single infection in mice [187]. Consequently, we questioned whether the 
the increase in disease severity following secondary infection was a result of primary 
disease worsening over time or if repeated infection compounded sequelae severity.  To 
determine whether secondary challenge resulted in more severe disease when compared 
to disease post primary infection, we compared weight ratios as a measure of objective 
disease severity for three independent untreated groups as weight positively correlated 
with disease severity score (Figure 2-7). As depicted in (Figure 2-8), untreated C. 
muridarum challenged animals were sacrificed fifty-six days post primary infection 
(Prim56) and were compared to untreated C.muridarum challenged mice sacrificed one 
hundred and twelve days post primary infection (Prim112). Prim56 and Prim112 mg/g 
ratio means remained stable despite a fifty-six day gap between sacrifice dates. Albeit not 
statistically significant, untreated C. muridarum challenged animals sacrificed fifty-six 
days post-secondary infection (Sec56), displayed an increase in mg/g ratio when 
compared to animals that only received primary infection. These data suggest severe 
disease is compounded with repeated chlamydial exposure as opposed to residual primary 
disease progressively worsening over time.  
 
 
IL-4 Is Detectable Late Following Reinfection and Positively Correlates with Disease 
Severity in Antibiotic-Treated Mice 
 
 Little is known about the cytokine milieu in the late stages of recurrent 
chlamydial infection. To address the question of which, if any, cytokines were detectable 
systemically during reinfection cycles, IFN-gamma, TNF-alpha, GM-CSF, IL-1B, IL-2, 
IL-4, IL-6, IL-8, IL-10, and IL-12 were simultaneously analyzed from individual sera 
samples collected from mice sacrificed 56 days post-secondary infection. Our results 
implicate a relatively short-lived TH1 response as suggested by a dominant IgG2 antibody 
response (Figure 2-2) and unremarkable detection of IFN-gamma, TNF-alpha, GM-CSF, 
IL-1B, IL-2, and IL-12 post recurrent infection (See appendices). Interestingly, IL-4, a 
potent inducer of TH2 immunity and a key defensive player against extracellular 
pathogens, was detected in the circulation and positively correlated with an objective 
measure of disease severity, weight ratios (Figure 2-9). Moreover, IL-4 detection in the 
observed sera analytes gradually increased with the deferred treatment of primary 
infection suggesting a TH2-independent role for IL-4 in this model.  
 
 
Chlamydia and Cellular Infiltrates Following Reinfection in Antibiotic-Treated Mice 
 
Genital tract sections were stained with H&E, NIMP-R14, CD68, CD4, or 
Toluidine to identify abundant cell types present in the genital tract after recurrent 
infection, including potential populations of known IL-4 secreting cells.  Late treated 
tissues stained with neutrophil-specific marker, NIMP-R14, revealed dense 
polymorphonuclear populations when compared to the residential populations observed 
in uninfected, untreated controls. Tissues excised from early treated animals  
(Figure 2-10B) displayed far fewer neutrophils than late treated groups (Figure 2-10A). 
Levels of T-cells expressing CD4 and macrophages expressing CD68 were comparable to   
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Figure 2-7. Weight ratio verses total severity score correlative analysis.  
 
Note: Pearson’s correlation was used to determine whether a relationship existed between 
severity scoring and weight ratio variables. Solid line represents the line of best fit. Blue 
circles represent individual mice (N=30). Red box highlights a significant positive 
correlation between the two variables, weight ratios and total disease severity, using a 
two-tailed analysis at 95% confidence interval of difference.  
 
  
0 5 10 15 20
0
1
2
3
4
5
Pearson r
  95% confidence interval
P value (two-tailed)
  P value summary
  Is the correlation significant? (alpha=0.05)
0.5105
0.1840 to 0.7355
0.0039
**
Yes
Weight
(mg/g)
S
e
v
e
ri
ty
 S
c
o
re
33 
  
 
 
Figure 2-8. Comparative analysis of weight ratios post-primary and secondary 
sacrifice in untreated intravaginally infected C57BL/6 mice.  
 
Note: Disease severity was assessed by dividing individual genital tract weights (in 
milligrams) by the corresponding total weight of the animal (grams) as described in 
Materials and Methods. Bars represent the mean weight ratio from three independent 
studies for each infection cycle/time group while error bars correspond to the standard 
error of the mean (SEM). Prim56 animals (N=3) were sacrificed 56 days post primary 
infection. Prim 112 animals (N=8) were sacrificed 112 days post-primary infection. 
Sec30 animals (N=9) were sacrificed 56 days post-secondary infection, totaling 112 days 
post initial chlamydial exposure.  
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Figure 2-9. Systemic IL-4 post recurrent infection.  
 
Note: Sera collected by submandibular bleed post-secondary infection was subjected to 
Luminex 10-Plex analysis to determine the cytokine milieu during late stages of recurrent 
infection. Individual samples were plated in duplicate and bars represent the mean IL-4 
concentration for each group (Panel A). To determine whether IL-4 correlated with 
disease, Pearson’s correlation was used (Panel B). A significant positive correlation (p= 
0.0462) was observed when IL-4 was plotted against the weight ratios of corresponding 
animals (N=30). Solid black line represents the line of best fit.   
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Figure 2-10. Neutrophil infiltrates post-secondary infection.  
 
Note: Immunohistochemistry evaluation using NIMP-R14, a neutrophil-specific marker, 
of genital tract samples taken 56 days post-secondary C. muridarum infection revealed 
marked increases in neutrophil influx in untreated controls (Panel A, x20) when 
compared to early treatment groups (Panel B, x20) and normal, non-infected tissue (Panel 
C, x20). Representative samples from each group are shown.  
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levels observed in untreated, uninfected controls (data not shown) assessed at the same 
time-point.  
 
As previously mentioned, we detected unexpected concentrations of systemic IL-
4 (Figure 2-9) despite seeing the antibody surrogate marker for TH1-related cytokines, 
IgG2 (Figure 2-4). As a result we sought to histologically identify known IL-4 producing 
cell populations. Using Toluidine Blue stain we identified a treatment dependent increase 
in genital tract mast cell populations, the number of mast cells increased the longer 
treatment was deferred (Figure 2-11). Furthermore, there was a significant correlation 
(p= 0.0090) between the severity of disease as assessed by weight ratios and mast cell 
density (Figure 2-12). We also identified eosinophil infiltrates in H&E stained genital 
tissue preparations but no statistically significant association was observed (Figure 2-13). 
 
 
Discussion 
 In this study, the main objective was to integrate various Chlamydia observations 
into a single, comprehensive mouse model of chlamydial genital infection. The 
reproductive health of women is of particular concern with current CDC Chlamydia 
surveillance data indicating increases in reported chlamydial infections, perhaps, in part, 
as a result of rapid antibiotic intervention. In contrast, rising infection rates are coupled 
with reduced complication rates in screened populations [131] [134] [188] despite 
evidence of adverse complications being linked to multiple or prolonged chlamydial 
exposures in human epidemiological studies [176] [177] [179].  Collectively, these 
observations underscore the importance of determining the impact of antibiotic 
intervention on the development of severe upper tract disease following repeated 
infection.  
 
In this C. muridarum model of genital infection, we showed that mice 
intravaginally infected and treated early during primary infection displayed rapid 
bacterial clearance kinetics in the lower genital tract, significantly reduced anti-
chlamydial IgG titer, and virtually no upper genital tract disease.  These results verify and 
validate a previous antibiotic study in C57BL/10 mice that concluded early antibiotic 
treatment reduced the development of natural immunity [162]. Our study expands on this 
model by extending observation on disease severity to post-secondary infection and by 
defining differences in disease localization.  Mice treated early during primary infection 
displayed mild disease severity scores (mean score of 1) in both uterine horn dilation and 
hydrosalpinx formation.  Conversely, untreated infected mice and mice treated later 
during primary infection displayed moderate to severe disease severity scores in the 
uterine horn (mean range of 2 to 3.3).  However, in the oviduct, significant differences 
were not observed between treatment groups suggesting either chlamydiae-related 
responses differ between these two tissues or severe endometrial disease limits the 
likelihood of oviduct disease. Interestingly, and perhaps not logically, mice that received 
treatment midway through the natural course of an active primary infection (14-28d) 
displayed elevated disease severity scores in both the uterine horn and the oviduct, albeit 
not significantly different from other treatment groups.  So far, we have not studied this 
phenomenon extensively but eradication of the organism soon after the initiation of  
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Figure 2-11. Mast cell infiltrate post-secondary infection. 
 
Note: Immunohistochemistry evaluation using Toluidine Blue, a mast cell identifying 
stain, of genital tract samples taken 56 days post-secondary C. muridarum infection 
revealed mast cells in all of the groups assessed. Organ specific mast cell density was 
determined by manually counting positively stained granulated mast cells in the genital 
tissue. Bars represent mean mast cell counts for each treatment group.  
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Figure 2-12. Mast cell infiltrate verses systemic IL-4 correlative analysis.  
 
Note: Organ specific mast cell density was determined by manually counting positively 
stained granulated mast cells in the genital tissue. A strong positive correlation between 
systemic IL-4 and mast cell infiltrate (r= 0.6682, p= 0.0090) was observed using 
Pearson’s correlation two-tailed testing at a 95% confidence interval. 
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Figure 2-13. Eosinophil infiltrate post-secondary infection.  
 
Note: Immunohistochemistry H&E staining of genital tract samples taken from mice 56 
days post-secondary infection with C. muridarum revealed eosinophils in untreated, 
uninfected animals (A, x40), early treatment groups (B, x20), and late treatment groups 
(C, x30). Thirty-six fields were randomly selected and counted (12 cervical fields, 12 
uterine horn fields, and 12 oviduct fields.) for each sample. No significant correlation 
between the number of eosinophils present in the genital tract and systemic IL-4 was 
found (D). Representative samples from each group are shown. 
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antibiotic treatment and detectable humoral antibody responses fail to explain the 
observation. Future characterization of the model, including but not limited to the cellular 
immune response, is of interest and should be investigated to elucidate the underlying 
immune mechanism involved.  
 
Histological analyses of various cellular populations suggest an influx of 
polymorphonuclear cells during late stages of recurrent urogenital infection. Using 
NIMP-R14, a neutrophil –specific marker, we observed an increase in neutrophils among 
late treated animals when compared to uninfected controls and early treated groups. This 
follows previous observations by our group [189] [190] and others [191] [192] [193] that 
cellular infiltrates composed of neutrophils correlate with the development of more 
severe disease. Data from our studies illustrate the sustained presence of neutrophils 
during late stages of recurrent infection (fifty six days post-secondary infection) and 
suggest that disease severity may be a function of sustained innate reactivity rather than 
the TH1-biased response that was observed in all animals, irrespective of disease severity. 
This expands the current paradigm of neutrophil influx as an early marker of infection 
into a potential mediator of disease outcomes and implies that modulation of neutrophil 
influx may improve chlamydiae-related disease severity and may be investigated as a 
potential way to improve reproductive health.   
 
Perhaps the most interesting finding in this investigation was the systemic 
detection of TH2-linked immune regulator, IL-4 (Figure 2-9), with greater detection of 
IL-4 corresponding with late treatment groups displaying the most severe disease. While 
our data support the current dogma of TH1-type responses playing a role in the resolution 
of infection as evidenced by a detectable IgG2-biased chlamydial-specific antibody 
response (Figure 2-4), they also suggest an alternative TH2 independent role for IL-4 
production during recurrent chlamydiae infection. Our data illustrate the development of 
chlamydial-induced genital tract pathology, with the severity of disease increasing the 
longer you defer antichlamydial treatment and with multiple rounds of chlamydial 
exposure. Following secondary exposure, a scenario in which we report exacerbated 
genital tissue damage, large amounts of IL-4 were detectable and gradually increased as 
the magnitude of disease increased. Our data compliments observations made by Holland 
et al of increased TH2-related cytokine production in patients with more severe disease 
[194]. Miquel et al reported that women with a history of Chlamydia trachomatis 
infection secrete cytokines consistent with TH2 immunity, specifically significant levels 
of IL-4, in response to ex vivo stimulation [195]. Collectively, these observations lead us 
to hypothesis a role for IL-4 in tissue repair. Recent reports have linked IL-4 to tissue 
repair and wound healing by alternatively activating macrophages and stimulating the 
expansion of IL-4 producing cells [196] [197] [198] [199] [200].  In line with these 
reports, we were able to detect both eosinophils and mast cells, known IL-4 producing 
cells, in our model. Furthermore, it is important to keep in mind that we detected a TH1 
response, at least early on during infection, as evidenced by an IgG2 biased antibody 
response.  This suggests that the production of IL-4 occurs later in the immunological 
cascade (following the production and secretion of chlamydial-specific antibody), which 
decreases the likelihood of IL-4 initiating the genital tract tissue damage observed (the 
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idea of IL-4 being an injury promoter) and points to the possibility of IL-4 playing a role 
in “injury response.” 
 
While we present data in support of the IL-4-driven injury response hypothesis, 
further study is necessary for hypothesis validation and mechanism delineation.  For 
instance, we proposed the transient production of TH1-related cytokines led to the 
detection of IgG2 isotypes during early infection cycles. Time course studies following 
the onset and dissipation of TH1-linked cytokines and IL-4 are key to verifying that 
proposal. While we know eosinophils and mast cells are capable of producing IL-4 and 
their presence in the genital tract implicates them as IL-4 sources, it would be useful to 
know if they are actually responsible for producing the detected IL-4. This can be 
accomplished by microarray analysis of IL-4 gene expression and subsequent ELISA 
assay for IL-4 production ex vivo. Additional experiments may also include looking at 
the upregulation of genes known to particulate in repair signaling pathways in genital 
tract-derived tissue and dispelling the possibility of IL-4 participating in the initial stages 
of disease development using IL-4-/- knockout mice.  
 
Rapid antibiotic treatment is a key component of current Chlamydia control 
initiatives that may influence infection rates and, more importantly, disease outcome 
trends on the population level, but assessing the impact of antibiotic intervention on 
severe disease development is difficult to address due to ethical concerns associated with 
delaying or withholding treatment in the human population. To this end, we interrogated 
the murine model for its potential to serve as a translational bridge between population-
based epidemiology and previous animal and human studies. Our results reaffirm the 
benefit of rapid antibiotic intervention in Chlamydia control efforts and suggest an added 
benefit during repeated infection even in the absence of antibiotic treatment. Although 
early-treated mice developed some upper tract disease after re-challenge, it was 
substantially less severe than the disease observed in groups where treatment was 
delayed.  This is of particular interest since previously screened and treated women 
commonly re-enter susceptible sexual networks, acquire a secondary infection, and fail to 
seek treatment due to the asymptomatic nature of Chlamydia trachomatis infection.  Most 
importantly, we provide support for IL-4 dependent tissue damage response following the 
induction of chlamydial-induced genital tract complications. We conclude that the 
integrated murine model is useful for studying the efficacy of antibiotic intervention at 
varying time-points with respect to disease severity but requires further characterization 
to elucidate potential mechanisms by which chlamydial pathogenesis occurs and is 
regulated, particularly as it pertains to the induction of IL-4. The dichotomy between cell-
mediated chlamydiae-related immune responses may not be as straightforward as we 
previously thought.  
 
  
42 
CHAPTER 3.    CHLAMYDIAL GENITAL TRACT SEQUELAE IS AGE AND 
STRAIN-DEPENDENT 
 
 
Introduction 
 Sexually transmitted Chlamydia trachomatis  is the causative agent of the most 
commonly reportable disease in the United States [147] and a small percentage of 
infected women develop reproductive and gynecologic complications such as chronic 
pelvic pain [170, 201-204], pelvic inflammatory disease (PID)[170] [201] [205] [206], 
involuntary infertility [170] [172] [201] [203] [206], and ectopic pregnancy [170] [172] 
[176] [201] [204] [206]. While many factors contribute to individual disease variability to 
chlamydiae [74] [75] [100] [207], the effects of biological determinants such as genetic 
predisposition and host age at the time of infection [208] [209] are largely unknown. 
Identification of host genetic factors is central to improving the quality of current disease 
animal models and understanding chlamydial-induced disease heterogeneity. Moreover, 
murine genetic studies may implicate novel pathway targets for individualized 
therapeutic intervention in humans. 
 
 Inbred mouse models have been extensively used to study host contributions to 
chlamydiae infection susceptibility [74] [75] [210] [211] [212] [213] [214] [215]. 
Cytokine induction and expression, H2 haplotypes, chlamydial species, and Th-1-
mediated responses have all been identified as factors that contribute to varying murine 
susceptibility. More recently, unbiased genome-wide approaches have been used to 
identify p47 GTPase genes encoded on chromosome 11 that confer resistance in mice to 
systemic models of C. trachomatis and C. psittaci infection, respectively [190] [216] 
[217].  Since, Miyairi et al have combined the high throughput forward genetic approach 
of BxD recombinant inbred strains with Bayesian network modeling to identify host 
pathways that modulate susceptibility to systemic chlamydial infection [78].  
 
 In the present investigation, we considered the age of the animal at time of 
infection and the genetic composition of the host when identifying differences in upper 
genital tract disease severity. We conclude that age and host genetic make-up are both 
important determinants of disease. 
 
 
Materials and Methods 
 
Mice 
 
Seven week old C57BL/6J (H-2b) and DBA/2J (H-2d) female mice (referred to as 
≤9wk animals) were commissioned from The Jackson Laboratory (Bar Harbor, ME, 
USA). Fourteen to 32-week old C57BL/6J and DBA/2J female mice (referred to as 
>14wks) were bred and maintained at our facility, which is fully accredited by the 
Association for Accreditation and Assessment of Laboratory Animal Care International. 
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The Animal Care and Use Committee at The University of Tennessee Health Science 
Center (Memphis, TN) approved all animal studies.  
 
 
Chlamydia Strain  
 
The Chlamydia muridarum (Weiss) strain was propagated in HeLa 229 cells and 
elementary bodies (EBs) were purified from infected cells by 30% density gradient 
centrifugation in Renograffin (E.R. Squibb and Sons, Princeton, NJ). Chlamydial titer 
was evaluated by infecting HeLa 229 cells and enumerating by indirect fluorescence 
microscopy as previously described. Stocks were stored at -80oC until use. 
 
 
Chlamydia muridarum Infection  
 
DBA/2J, C57BL/6J, and BXD mice were pretreated with progesterone to 
synchronize the estrous cycle and stabilize the target genital epithelium.  Pretreatment 
consisted of two subcutaneous injections of 2.5 mg medroxyprogesterone acetate 
injectable suspension (Sicor, Irvine, CA) in 0.1 mL phosphate buffered saline (PBS), 
given at 10 and 3 days prior to infection. Mice were inoculated with 5000 inclusion-
forming units (IFUs) contained in 5 uL sucrose phosphate-buffered glutamic acid (SPG) 
via the vaginal vault with a filtered micropipettor on day 0. Five animals from each group 
(DBA/2J-≤9wks, DBA/2J->14wks, C57BL/6J-≤9wks, and C57BL/6-2J->14wks) were 
sacrificed 40-days post infection. For rechallenge studies, five animals from each group 
were progesterone treated at day 30 and intravaginally challenged with 5000 IFU at day 
40. All rechallenged animals were euthanized 30 days post reinfection, seventy days post- 
primary infection.  
 
 
Pathology Assessment  
 
Individual mice were weighed to obtain total body weight in grams. In situ 
macroscopic examinations were performed for evidence of upper genital tract 
abnormalities immediately following sacrifice.  Genital tissues were then aseptically 
removed, photographed, and weighed to obtain organ weight in micrograms. Severity 
scores were determined for the uterine horn and oviducts separately: 0, no significant 
dilatation; 1, mild dilatation of a single cross-section; 2, one to three dilated cross-
sections; 3, greater than three dilated cross-sections; 4, confluent pronounced dilation. 
Scores assigned to individual mice were averaged to obtain the mean severity score for 
each group of animals. Weight ratios (organ weight-milligrams/ total body weight-grams) 
were used as an objective validation tool for upper genital tract severity scoring.  
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Results 
 
C57BL/6J Exhibit Age-Dependent Upper Genital Tract Sequelae Post-Primary 
Intravaginal Infection 
 
DBA/2 and C57BL/6 female animals of varying ages were intravaginally infected 
with C. muridarum as described in materials and methods. Individual mice were scored 
according to the localization of disease 40 days post infection. Nine out of 20 animals 
(45%) assessed developed hydrosalpinx with B6-≤ 9wk animals displaying significantly 
more oviduct disease (p< 0.001) when compared to all other animal groups (Figure 
3-1A). Twenty percent of DBA/2, regardless of age, displayed mild oviduct dilatation 
indicated by a mean severity score of 0.23. Conversely, discordant oviduct severity 
scores were observed among C57BL/6J-≤ 9wk and C57BL/6J->14wk groups. A 
moderate oviduct severity score of 2.2 was observed in B6-≤ 9wk animals while B6-
>14wk animals displayed mild oviduct involvement with a mean score of 0.4. No 
significant differences were observed in endometrial dilatation among groups, 
irrespective of inbred strain or age (Figure 3-1B).  
 
 
Secondary Intravaginal Infection Exacerbates Chlamydial-Induced Upper Genital 
Tract Complications 
 
 We hypothesized that recurrent chlamydial exposures would result in worse 
disease when compared to animals that received primary infection alone. To test this 
hypothesis, DBA and B6 female mice were intravaginally infected at day 0 and 
rechallenged at day 40 as described in materials and methods. Thirty days after 
rechallenge, genital tissues were aseptically harvested and assessed for oviduct and 
uterine horn dilatation. As we hypothesized, secondary disease exacerbated negative 
disease outcomes in both strains and age groups (Figure 3-2) when compared to the 
corresponding groups that only received a primary infection (Figure 3-1). Sixteen out of 
21 animals (76%) examined after secondary infection developed oviduct pathology as 
opposed to 45% of primarily infected animals. Fourteen out of 21 animals (66.6%) 
examined after secondary infection developed uterine horn pathology as opposed to 30% 
of primarily infected animals.  
 
 
C57BL/6 Mice Are More Susceptible to Chlamydial-Induced Upper Genital Tract 
Complications When Compared to DBA/2J Mice 
 
 DBA and B6 female mice were intravaginally infected at day 0 and rechallenged 
at day 40 as described in materials and methods. Thirty days after rechallenge, genital 
tissues were aseptically harvested and assessed for oviduct and uterine horn dilatation. 
Oviduct disease observed in C57BL/6-≤ 9wk animals was significantly worse (mean 
severity score 3.6) than that observed in DBA/2-≤ 9wk and DBA/2->14wk animals with 
mean scores of 0.8 and 1.2, respectively. Additively, C57BL/6->14wk animals displayed 
significantly more severe oviduct disease than that seen in DBA/2-≤ 9wk or DBA/2  
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Figure 3-1. Upper genital tract disease incidence and severity post-primary 
infection.  
 
Note: DBA/2 and C57BL/6J female mice were intravaginally infected with Chlamydia 
muridarum as described in materials and methods. Forty days after infection, mice were 
sacrificed and pathology was assessed grossly. The left figure (Panel A) displays oviduct 
disease severity and disease incidence by inbred strain and age group. The right figure 
(Panel B) displays uterine horn disease severity and disease incidence by inbred strain 
and age group. 5 animals were assessed per group and bars indicate mean severity scores. 
* and ** indicate significant differences (p≤ 0.01 and p≤ 0.001) as determined by one-
way ANOVA with post hoc Newman-Keuls Multiple Comparison Test. Data are 
representative of two independent studies. 
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Figure 3-2. Upper genital tract disease incidence and severity post-secondary 
infection.  
 
Note: DBA/2 and C57BL6 female mice were intravaginally infected and rechallenged 
with Chlamydia muridarum as described in materials and methods. Thirty days post-
secondary infection, mice were sacrificed and pathology was assessed grossly. The left 
figure (Panel A) displays oviduct disease severity and incidence by inbred strain and age 
group. The right figure (Panel B) displays uterine horn disease severity and incidence by 
inbred strain and age group. 5-6 animals were assessed per group and bars indicate mean 
severity scores. * indicate significant differences (p<0.01) as determined by one-way 
ANOVA with post hoc Newman-Keuls Multiple Comparison Test. Data are 
representative of two independent studies. 
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->14wk animals. Although uterine horn severity assessments did not result in statistically 
significant differences, B6-≤ 9wk animals consistently displayed moderate disease 
severity as indicated by a mean score of 2 while B6->14wk endometrial involvement was 
comparable to that observed in DBA/2 animals. 
 
To remove any unintentional disease bias imposed by using the quantitative 
severity scoring system, we assessed disease severity as a function of organ weight in 
milligrams divided by total body weight in grams (Figure 3-3).  We have previously 
observed a direct correlation between severe disease and increased weight ratios given 
genital abnormalities that involve dilatation of murine oviduct and uterine horn tissues 
increase the ratio numerator value-organ weight in milligrams (Figure 2-7). Weight 
ratios compliment severity score data in that secondary infection results in worse disease 
when compared to animals of the same strain and age group. Moreover, C57BL/6-≤ 9wk 
animals are most susceptible to chlamydial-induced upper genital tract complications 
evidenced by significant differences observed in recurrent infection oviduct severity 
scores and objective weight ratio analysis. 
 
 
Discussion 
 Individual differences in disease susceptibility as a result of infectious agents 
exist in the population. For example only a small subset of women with uncomplicated 
chlamydial genital infection go on to develop severe upper genital tract 
complications[170]. Furthermore, adolescent females are more likely to contract 
Chlamydia than any reported age group [185] [218] [219]. In the United States alone, the 
reported 2011 rates of sexually transmitted chlamydial infection for women between the 
ages of 15-19 and 20-24 were 3416.5 and 3722.5 per 100,000 population, respectively 
[147]. The reported rate for adolescents between the ages of 15-19 yrs is over five times 
the national rate of 648.9 per 100,000 population and almost six times the national rate 
for young women between the ages of 20-24 yrs. These rates are particularly alarming 
considering the rate for women in their mid-forties to early fifties is only 35.8 per 
100,000 population [147]. Taken together, current epidemiological trends highlight the 
need for chlamydial models to account for biological factors such as host age when 
assessing incidence and severity of chlamydiae-induced reproductive complications.  
 
 In this study, chlamydial-induced disease outcomes were largely dependent on the 
mouse age and strain used to model urogenital infection. C57BL/6-≤ 9wk mice were 
more susceptible to oviduct pathology when compared to DBA/2 mice as evidenced by 
mean severity score post primary (Figure 3-1A) and secondary infection cycles (Figure 
3-2A). In addition to extra-strain disease variation, intra-strain disease variation among 
B6 was shown to be age-dependent in the oviduct post primary infection and, albeit not 
statistically significant, in the oviduct and uterine horn post-secondary infection. In 
addition to the four-tiered semi-quantitative severity scoring system, these results were 
objectively validated with weight ratio analysis (Figure 3-3). BL/6-≤ 9wk animals 
display significantly more disease as evidenced by weight ratios when compared to   
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Figure 3-3. Weight ratio disease severity validation post-primary and secondary 
intravaginal infection.  
 
Note: DBA/2 and C57BL6 female mice were intravaginally infected and rechallenged 
with Chlamydia muridarum as described in materials and methods. Weight ratios were 
determined by dividing individual organ weights (milligrams) by total body weight 
(grams). Ratios were averaged to calculate the mean value for each group (indicated by 
bar). Error bars depict the standard error of the mean. * indicate significant differences 
(p< 0.05) as determined by one-way ANOVA with post hoc Newman-Keuls Multiple 
Comparison Test. ** indicate significant differences (p< 0.01) as determined by one-way 
ANOVA with post hoc Newman-Keuls Multiple Comparison Test.  Data are 
representative of two independent studies. 
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> 14wk animals with the same genetic background. Interestingly, disease severity as a 
function of weight observed in DBA/2 animals remained consistent irrespective of age or 
disease localization.  
While inter-strain susceptibility variations have been appreciated for some time 
[74] [75] [210] [220], our studies suggest C57BL/6 animals are susceptible to 
chlamydial-induced genital tract complications when compared to DBA/2 mice as 
determined by semi-quantitative severity scoring (Figures 3-1 and 3-2) and weight ratios 
(Figures 3-3). Kaltenboeck et al also found that C57BL/6 animals were susceptible to 
chlamydial-induced disease using a respiratory murine model of infection [221].  In their 
studies C57BL/6 mice developed severe pneumonia while BALB/C mice were 
completely void of symptoms following intranasal priming with C. psittaci and 
subsequent challenge.  Interestingly, our results and those seen in the Kaltenboeck model 
conflict with genital studies proposing a resistant phenotype for C57BL/6 when 
compared to C3H and BALB inbred strains, both of which are commonly referred to as 
susceptible strains given their increased chlamydial shedding and longer courses of 
infection when compared to C57BL/6 mice. Although we have not delineated a 
mechanism for the results seen in our study, immunological validation is warranted and 
currently underway. The discrepancies observed between our results and those published 
by others may also be attributed, at least in part, to differences in the strains of Chlamydia 
used, inoculum dosage, murine strains, multiple rounds of infection, and variation in what 
is defined as resistance or susceptibility (I. E. reduced shedding, shorter infection course, 
infertility, eradication of the infectious agent in the lower and upper genital tract, or the 
development of upper genital tract sequelae). 
As many researchers developing infectious disease models, we are interested in 
identifying human correlates of phenotypic differences seen in our model. Studies are 
currently underway using B (C57BL/6) x D (DBA/2J) recombinant inbred mouse strains 
to identify genetic factors that may modulate disease susceptibility in an age-dependent 
manner. By interrogating the GeneNetwork database using a forward genomic approach, 
we hope to identify genes associated with the modulation of oviduct and uterine horn 
disease severity in an age and strain dependent manner. More importantly, we are 
interested in identifying human correlates for the potential murine-derived phenotypic-
genetic links observed in our model.  
 While studies aimed at delineating causal mechanisms for the age and strain 
dependence reported here are currently underway, these initial observations have 
immediate implications for the use of mouse models in understanding chlamydial-
induced disease. Furthermore, these data suggest that the host genetic contribution to 
genital pathogenesis may be more complex than previously appreciated.   
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CHAPTER 4.    IMMUNIZATION WITH C. MURIDARUM OUTER MEMBRANE 
COMPLEX FAILS TO PROTECT AGAINST UPPER GENITAL TRACT 
COMPLICATIONS IN A MURINE MODEL OF GENITAL INFECTION 
 
 
Introduction  
Chlamydia trachomatis is the causative agent of the most commonly reported 
sexually transmitted disease in the United States, Chlamydia, and a public health threat 
worldwide [56] [63] [147] [222]. Despite the overwhelming global presence of 
chlamydial infection, many cases are undiagnosed due to asymptomatic infection and 
may serve as a reservoir for infection [175] [223]. Regardless of whether Chlamydia 
trachomatis infection is symptomatic or asymptomatic, women with genital infections 
may develop long-term sequelae like pelvic inflammatory disease (PID), ectopic 
pregnancy, involuntary infertility, and miscarriage [169] [170]. Antibiotic therapy is 
currently effective in clearing the organism from the lower genital tract but the 
emergence of antibiotic resistance, although rare, is a viable concern [224] [225] [226] 
227].  Currently, rapid antibiotic intervention is a key component of Chlamydia control 
programs [173] [175] and may serve as the selective pressure necessary for the evolution 
of antibiotic resistant human strains. Taken together, the high rate of asymptomatic 
infection and the potential for developing antibiotic resistance despite the current 
availability of effective antimicrobial therapies underscore the need for a safe and 
efficacious vaccine. 
 
Trachoma vaccine trials using whole organisms, both inactivated and live, were 
performed decades ago and are perhaps the most notable vaccination studies to date. 
Unfortunately, a subset of individuals who were vaccinated and reexposed to Chlamydia 
experienced significantly more severe disease when compared to non-vaccinated cohorts 
[124] [228] [229]. While no human trials have been untaken since the trachoma study, 
researchers have continued the quest to identify safe chlamydial antigens that elicit 
immunological memory- the basis of all vaccines.  
 
A number of Chlamydia trachomatis- associated antigenic proteins have been 
described, particularly proteins associated with the cell surface. Many studies have 
focused on developing a subunit-based vaccine using Chlamydia trachomatis major outer 
membrane protein (MOMP) as the antigen [230] [231]. MOMP has been an attractive 
candidate because it constitutes an approximated 60% of the total outer membrane mass 
and is immune-assessable due to its location on the chlamydial surface [21] [125]. 
Although MOMP seemed promising, its ability to induce protection has been sketchy at 
best, displaying varying protection in small animal models and higher order primates 
[232] [233] [234] [235] [236] [237] [238] [239] [240] [241]. There may be several 
reasons for the variation seen in the previously mentioned studies including but not 
limited to the animal model and strain(s) used, immunization site, challenge route, 
definition of protection (I.E. reduction in shedding, fertility, cytokine production, 
antibody titer, or sequelae formation) , and antigen preparation. Indeed, one of the main 
lessons taken from previous MOMP studies is that conformational integrity of the 
chlamydial membrane may increase protection following chlamydiae challenge.  As a 
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result, we elected to use detergent-extracted chlamydial outer membrane complexes 
(COMCs) as described by Caldwell et al [125] in the preliminary studies outlined later in 
this Chapter. Sarkosyl-Insoluble COMC was found to be structurally intact and 
maintained the shape observed in protein-rich infectious chlamydial particles, elementary 
bodies (EBs). 
 
In the pages to follow, I outline experiments evaluating the efficacy of COMC as 
a potential antigen in both systemic and genital models of chlamydiae infection. As a 
disclaimer, these studies are in their infancy at best and should not be interpreted as 
complete studies. Several gaps exist in the experiments outlined hereafter but these data 
do provide interesting tangents that may serve as the basis for future experimental 
direction. To that end, our initial results in the systemic model showed promise by 
negating the effects of lethal interperitoneal chlamydial doses.  Conclusions originating 
from studies in the urogenital murine model were more muddled when compared to the 
lethal model. Despite the inconclusive nature of the genital tract model results, we 
examined the potential benefits of alum, an adjuvant known to generate a TH2 cell-
mediated response, in the prevention of severe genital sequelae. 
 
 
Materials and Methods (Systemic Lethal Model) 
 
Mice 
 
Female DBA/2J mice were purchased from Jackson Laboratories at 7-8 weeks of 
age. They were housed in the University of Tennessee Health Science Center animal 
facility and animal protocols were performed in compliance with institutional IACUC 
and federal mandates. 
 
 
Chlamydiae 
 
Chlamydia psittaci 6BC was propagated in the murine fibroblast cell line L929 
(ATCC; Manassas, VA) and stored at -80o C. Titers were determined by infecting L929 
cells plated at a density of 2 x 105 cells/well in 24- well plates (Corning Costar 
Corporation, Cambridge, MA), with tenfold dilutions of thawed stock.  Infected 
monolayers were incubated for 48 hours, methanol fixed, and chlamydial inclusions were 
enumerated using fluorescent staining with FITC-conjugated anti-chlamydial 
lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated, Concord, MA).  
 
 
COMC Extraction 
 
Chlamydia psittaci 6BC COMC was purified as described by Caldwell et al [125]. 
In brief, C. psittaci 6BC stock was thawed at room temperature and suspended in 5mL of 
pH 8 phosphate buffered saline (PBS) containing 2% dipolar ionic Zwittergonic detergent 
and 1.5 mm EDTA.  A dry ice bath was used to precipitate proteins and the resulting 
52 
suspension was sonicated, in series, 3 times with 1 minute iced incubation periods 
between each round of sonication.  The cell suspension was incubated for 3 hours at 37o 
C and ultracentrifuged at 32, 700 rotations per minute (RPM) for 1hour.   
 
 
Immunization and Infection 
 
DBA/2J mice were intramuscularly mock immunized with 100mL of sterile 
Dulbecco’s phosphate buffered saline (PBS), viable whole elementary bodies (EBs) of 
6BC (5 x 102 IFU in 100mL of sterile PBS), or 6BC-derived COMC (40mg total) in 
100mL of PBS, respectively.  Mice received a total of two immunizations at days -14 and 
-7.  On day 0, mice were intraperitoneally challenged with a low dose (1 x 103 IFU, 
equivalent to 1000 LD50) or a high dose (1 x 10
5 IFU, equivalent to 100000 LD50) and 
monitored for survival.  Surviving animals were sacrificed 15 days post infection 
irrespective of immunization regimen.  
 
 
Results (Systemic Lethal Model)  
Our laboratory was instrumental in developing a systemic interperitoneal model 
of chlamydial disease using C. psittaci 6BC, a zoonotic to which mice are highly 
susceptible. Using the systemic model Byrne and colleagues were able to elucidate basic 
concepts concerning interferon-gamma and Chlamydia psittaci clearance [242] [243] 
[244].  Unpublished data from our laboratory showed that doses as low as 1 EB can cause 
mice to succumb to infection within 10 days of initial C. psittaci challenge. These data 
provided the basis for using the systemic model of chlamydiae infection to elucidate 
COMC immunogenicity.  One hundred percent of mice immunized with viable 6BC 
Chlamydia psittaci elementary bodies (EBs) survived challenge and recovered from 
infection irrespective of the challenge dose.  Conversely, all mock PBS immunized mice 
succumbed to infection within 11 days of interperitoneal challenge.  20% of COMC 
antigen immunized mice survived an inordinately high dose challenge and went on to 
recover from infection (Figure 4-1).  Moreover, 60% of mice immunized with 6BC 
Chlamydia psittaci -derived antigen survived and recovered from lethal challenge 
(Figure 4-2). 
 
Despite the rigor associated with the systemic chlamydial intraperitoneal murine 
model, COMC preparations were capable of eliciting partial protection against lethal 
challenge. Both immunizing doses, 102 and 105 IFU, supersede the LD50 and highlight the 
sensitivity of DBA/2J inbred mice to 6BC Chlamydia psittaci intraperitoneal infection as 
previously illustrated by the Byrne laboratory. Collectively, these data suggested COMC-
induced partial protection with homologous challenge and justified transitioning these 
studies into the urogenital model which would display more subtle read-outs. 
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Figure 4-1. High dose 6BC C. psittaci systemic infection survival curve.  
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Figure 4-2. Low dose 6BC C. psittaci systemic infection survival curve. 
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Materials and Methods (Urogenital Model)  
 
Mice  
 
Female DBA/2J mice were purchased from Jackson Laboratories at 7-8 weeks of 
age. They were housed in the University of Tennessee Health Science Center animal 
facility and animal protocols were performed in compliance with institutional IACUC 
and federal mandates. 
 
 
Chlamydiae 
 
 Chlamydia muridarum (Weiss) was propagated in the human epithelial cell line 
HeLa 229 (ATCC; Manassas, VA) and stored at -80o C. Titers were determined by 
infecting HeLa 229 cells seeded at a density of 2 x 105 cells/well in 24- well plates 
(Corning Costar Corporation, Cambridge, MA), with tenfold dilutions of thawed stock.  
Infected monolayers were incubated for 48 hours, methanol fixed, and chlamydial 
inclusions were enumerated using fluorescent staining with FITC-conjugated anti-
chlamydial lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated, 
Concord, MA).  
 
 
COMC Extraction 
 
Chlamydia muridarum COMC was purified as described by Caldwell et al [125]. 
In brief, C. muridarum stock was thawed at room temperature and suspended in 5mL of 
pH 8 phosphate buffered saline (PBS) containing 2% dipolar ionic Zwittergonic detergent 
and 1.5 mm EDTA.  A dry ice bath was used to precipitate proteins and the resulting 
suspension was sonicated, in series, 3 times with 1 minute iced incubation periods 
between each round of sonication.  The cell suspension was incubated for 3 hours at 37o 
C and ultracentrifuged at 32, 700 rotations per minute (RPM) for 1hour. 
 
 
Immunization and Infection 
 
DBA/2J mice were intramuscularly immunized with 100mL of sterile Dulbecco’s 
phosphate buffered saline (PBS), 100mL of sterile Dulbecco’s phosphate buffered saline 
(PBS) and 25ug of alum, live C. muridarum elementary bodies (5 x 102 IFU in 100mL of 
sterile PBS), 25ug of Chlamydia muridarum-derived COMC in 100mL of PBS, or 25ug 
of Chlamydia muridarum-derived COMC in 100mL of PBS and 25ug of alum.  Mice 
received a total of two immunizations at days -14 and -7.  One week prior to challenge, 
the estrous cycle was synchronized by subcutaneous injection of 2.5mg of 
medroxyprogesterone acetate (Sicor, CA). On day 0, mice were intravaginally challenged 
with 2 x 103 IFU, a non-lethal dose of C. muridarum.  
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Results (Urogenital Model)  
C. muridarum and C. psittaci-derived COMC preparations were compared by 
commassie-stained SDS-Page gel and displayed comparable banding patterns  
(Figure 4-3).  As expected, animals intramuscularly immunized with viable whole C. 
muridarum elementary bodies and intravaginally challenged with 5 x 103 IFU displayed 
the most severe disease when compared to other immunization groups as evidenced by 
dilation of the uterine horns and reddening of the genital tract (Figure 4-4A). Mock 
immunized animals (Figure 4-4B) also displayed fluid accumulation in the uterine horn, 
although to a lesser extent when compared to the live immunized group. COMC 
immunized animals displayed less severe disease when compared to live immunized 
groups but still displayed mild to moderate dilation and reddening (Figure 4-4D). While 
animals immunized with COMC-alum displayed mild reddening, dilation was not 
observed (Figure 4-4E). Lastly but most intriguingly, animals immunized with the PBS-
alum combination displayed no dilation or substantial reddening (Figure 4-4C). 
 
While we hypothesized that alum would augment protection elicited by COMC 
antigen immunization despite its polarity toward a Th2-type response, we were perplexed 
by the observation seen in PBS-alum immunized groups.  Unexpectedly, the alum 
adjuvant seemed to negate the development of severe genital tract sequelae induced by 
exposure to C. muridarum intravaginal infection.  The study described below followed as 
an attempt to assess whether alum alone was capable of negating the development of 
upper genital tract sequelae following C. muridarum intravaginal infection. 
 
 
Materials and Methods (Alum Study)  
 
Mice 
 
Female C57BL/6J mice were purchased from Jackson Laboratories at 7-8 weeks 
of age. They were housed in the University of Tennessee Health Science Center animal 
facility and animal protocols were performed in compliance with institutional IACUC 
and federal mandates.   
 
 
Chlamydiae  
 
Chlamydia muridarum (Weiss) was propagated in the human epithelial cell line 
HeLa 229 (ATCC; Manassas, VA) and stored at -80o C. Titers were determined by 
infecting HeLa 229 cells seeded at a density of 2 x 105 cells/well in 24- well plates 
(Corning Costar Corporation, Cambridge, MA), with tenfold dilutions of thawed stock.  
Infected monolayers were incubated for 48 hours, methanol fixed, and chlamydial 
inclusions were enumerated using fluorescent staining with FITC-conjugated anti-
chlamydial lipopolysaccride antibody (Fitzgerald Industries Internation Incorporated, 
Concord, MA).  
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Figure 4-3. Comassie stained SDS-Page gel of C. muridarum (MoPn)-derived 
COMC and C. psittaci (6BC)-derived COMC preparations. 
 
Note: Chlamydiae COMC preparations were extracted as previously described in Chapter 
4. Protein concentrations were determined by Modified Lowry Protein Assay and 
visualized by SDS-Page gel. Molecular weight protein standard (shown on left) were 
used to approximate the molecular weight of visualized bands. 
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Figure 4-4. C. muridarum-derived COMC immunization study gross pathology. 
 
Note: Representative photos of genital gross pathology post homologous C. muridarum immunization and challenge. Photo (A) is 
representative of live immunizations. Photo (B) is representative of mock immunized animals. Photo (C) is representative of mock-
alum immunized animals. Photo (D) is representative of COMC immunized animals and photo (E) represents animal cohorts 
immunized with COMC-alum. Black arrows point out selected areas of dilatation, reddening, and hydros0alpinx formation. 
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Immunization and Infection 
 
C57BL/6J mice were intramuscularly immunized with 100mL of sterile 
Dulbecco’s phosphate buffered saline, 100mL of sterile Dulbecco’s phosphate buffered 
saline and 25ug of alum (Thermo Scientific), live C. muridarum elementary bodies (5 x 
102 IFU in 100mL of sterile PBS), or a mixture of live C. muridarum (5 x 102 IFU in 
100mL of sterile PBS) and 25ug of alum. Mice received two immunizations one week 
apart and were treated subcutaneously with 2.5mg of medroxyprogesterone acetate 
(Sicor, CA) at days -9 and -3 to synchronize the esterous cycle and enhance mouse 
susceptibility to chlamydial infection.   On day 0, mice were intravaginally challenged 
with 2 x 103 IFU Chlamydia muridarum in 10uL of PBS. Animals that were immunized 
and challenged were sacrificed 35 days post infection. Immunized animals that did not 
receive an infection were sacrificed 21 days after day 0.  
 
 
Pathology Assessment 
 
Before removing the genital tissue, an in situ gross examination was performed 
for evidence of chlamydial-induced abnormalities such as uterine horn dilation and 
hydrosalpinx formation. Genital tracts were aseptically removed, photographed, 
subjected to macroscopic inspection, and assigned a severity score on the day of sacrifice. 
 
 
Results (Alum Study)  
 
Immunogens without Intravaginal Chlamydia muridarum Challenge Do Not Induce 
Severe Upper Genital Tract Sequelae Formation  
 
Female C57BL/6J mice were intramuscularly immunized with alum adjuvant, 
viable C. muridarum and alum adjuvant, viable C. muridarum, or mock immunized with 
sterile PBS according to the timeline displayed in (Figure 4-5). Genital tracts from each 
animal were aseptically removed, weighed, photographed, and grossly assessed for upper 
genital tract sequelae formation three weeks after day 0.  Two non-immunized C57BL/6 
mice, of the same age and gender, were used as a reference. As hypothesized, 
hydrosalpinx formation was not observed in any of the immunization groups (Figure 
4-6). Negligible increases in dilation of the uterine horns were observed in mock, C. 
muridarum and alum adjuvant, and C. muridarum alone immunized animals. Although 
these increases were minimal, they were documented by granting the lowest severity 
score possible (Figure 4-7).  Overall, genital tract tissues, regardless of immunization 
group were comparable to that observed in the two non-immunized, non-challenged 
reference samples. 
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Figure 4-5. Alum study experimental timeline.  
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Figure 4-6. Oviduct pathology severity of non-challenged immunized groups.  
 
Note: Solid line represents the mean of each immunogen group. Symbols represent 
individual mice (N=5 per group except for normal control).  
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Figure 4-7. Uterine horn pathology severity of immunized, non-challenged 
groups.  
 
Note: Solid bars represent the mean severity score for each immunogen group. Symbols 
represent individual animals (N=5 per group except for normal controls). 
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Alum Alone Does Not Negate the Development of Severe Upper Genital Tract 
Complications 
 
Female C57BL/6J mice were intramuscularly immunized with alum adjuvant, 
viable C. muridarum and alum adjuvant, viable viable C. muridarum, or mock 
immunized with sterile PBS according to the timeline displayed in (Figure 4-5). All 
immunization groups were intravaginally challenged with 2 x 103 IFU of Chlamydia 
muridarum. Genital tracts from each animal were aseptically removed, weighed, 
photographed, and grossly assessed for upper genital tract sequelae formation and 
severity 35 days post infection.  Three female C57BL/6 mice which were not immunized 
or challenged were used as a negative reference. 
 
Unlike their non-challenged counterparts (Figure 4-6), all immunization groups 
displayed some level of oviduct disease (Figure 4-8). 40% of mock immunized animals 
displayed unilateral hydrosalphinx formation while 20% displayed bilateral oviduct 
involvement. 20% of animals immunized with C. muridarum or C. muridarum and alum 
adjuvant exhibited unilateral oviduct disease. Interestingly, 20% of animals immunized 
with alum adjuvant alone displayed bilateral hydrosalpinx while unilateral oviduct 
pathology was observed in 40% of the same immunization group.  
 
 Uterine horn dilation was seen in all groups immunized (Figure 4-9). 60% of 
animals immunized with C. muridarum alone displayed mild dilation with a mean 
severity score of approximately 1.  Eighty percent of animals immunized with C. 
muridarum and alum adjuvant were found to have dilated uterine horns with 60% of 
those being mildly dilated and 20% displaying moderate dilation.  Only 20% of alum 
adjuvant immunized animals displayed uterine involvement, whereas, 60% of mock 
immunized animals experienced uterine horn dilation.  
 
 
Discussion 
Although C. trachomatis lower genital tract infections may resolve without 
adverse reproductive complications [164] [245] [246], a subset of those infected may 
develop upper genital tract sequelae. Presently, Chlamydia control initiatives focus on 
identifying and treating individuals before, at least in humans, irreversible tissue damage 
occurs. This approach is complicated by the fact that most human chlamydial infections 
are often asymptomatic. As a result, the most effective way of controlling chlamydiae 
infections would be to develop a vaccine. Although the studies outlined in this Chapter 
fail to provide definitive answers pertaining to protection against chlamydial infection, 
they do highlight the need for ongoing vaccine development initiatives to consider the 
pathogenesis approach given the overarching goal of any Chlamydia trachomatis 
vaccination effort would be to preserve reproductive health by preventing the 
development of severe disease manifestations. 
 
In the systemic model of chlamydial infection we showed that a detergent-
extracted preparation of C. psittaci-derived COMC protected mice from lethal 
intraperitoneal challenge.  To our knowledge, this is the first study of its kind and the  
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Figure 4-8. Oviduct pathology severity of immunized and challenged groups.  
 
Note: Solid bars represent the mean severity score for each immunogen group. Symbols 
represent individual animals (N= 5 per group except for normal control). 
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Figure 4-9. Uterine horn pathology severity of immunized and challenged groups.  
 
Note: Solid bar represents the mean for each immunogen group. Symbols represent 
individual animals (N = 5 per group except for normal control).  
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results inspired us to examine the efficacy of COMC in the C. muridarum urogenital 
model given the fact that mice intravaginally infected with Chlamydia muridarum 
develop genital sequelae similar to that observed in human populations. Seeing as the 
development of genital morbidities such as hydrosalpinx and endometritis are more 
subtle than the mortality (survival vs death) end point observed in the systemic model, we 
opted to co-administer alum adjuvant in subsequent genital tract experiments as a way of 
enhancing the responses observed with homologous COMC antigen. Additionally, 
aluminum hydroxide, aluminum phosphate, and aluminum sulfate are the only vaccine 
adjuvant formations licensed in the United States and are currently being used in vaccines 
directed against the intracellular pathogens, hepatitis B virus (HBV) and human 
papilloma virus (HPV) [247].  
 
In our studies, COMC-alum immunized groups (Figure 4-1E), as hypothesized, 
fared better than mock immunized groups (Figure 4-1B) and live immunized groups 
(Figure 4-1A) displaying no increases in uterine horn or hydrosalpinx formation. As we 
hypothesized, DBA/2J mice immunized with live C. muridarum and challenged with C. 
muridarum displayed the most severe pathology with both endometrial dilation and 
oviduct inflammation (Figure 4-1A).  These findings complement our studies and the 
studies of others that suggest chlamydial infection recurrence increases the risk for 
reproductive sequelae [177] [179] [248]. 
 
By far the most interesting observation was the fact that alum adjuvant and PBS 
immunized animals displayed no signs of chlamydial-induced pathology or reddening 
which is indicative of inflammation. While Th2-driven responses such as those prompted 
by the alum adjuvant have been shown to promote immunopathology in chronic diseases 
such as schistosomiasis [249] [250], autoimmune diseases, and allergies, more recent 
studies have implicated TH2-linked responses to tissue repair and wound healing. As a 
result, we hypothesized that a Th2-type response may play a protective role in upper 
genital tract disease formation. 
 
To experimentally address the effects of alum adjuvant on chlamydial-induced 
genital tract pathology we immunized female C57BL/6J mice with alum adjuvant, alum 
and whole organism C. muridarum, or intact C. muridarum organisms alone. Based on 
the observations seen in the COMC urogenital studies, we hypothesized that alum only 
severity scores would be on par with severity scores associated with non-immunized, 
non-challenges animals (negative controls). Interestingly, animals immunized with alum 
adjuvant alone displayed severity scores comparable to those observed in alum/C. 
muridarum and C. muridarum alone immunization groups (Figure 4-9). While the alum 
alone observation was unexpected, we were encouraged by the fact that all immunization 
groups exhibited less severe disease, as indicated by mean severity score, than the mock-
immunized PBS group which complemented the results seen in the preliminary COMC 
urogenital  studies (Figure 4-4 and Figure 4-9). 
 
There are at least two, not mutually exclusive, explanations for the discrepant 
results seen in the alum adjuvant alone group. One is the mouse inbred strain we used in 
the follow-up studies. We substituted the DBA/2J mouse strain originally used in the 
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COMC studies for the C57BL/6J inbred strain because B6 animals used in ongoing, 
unrelated studies in our laboratory routinely exhibit more severe genital tract disease 
when compared to DBA/2J animals.  We hypothesized that by using the ‘more severe’ 
B6 background we would stratify the results seen between groups, making the potential 
benefits of alum immunization easier to identify. We know that the enhancement effects 
of alum are less pronounced than that of other adjuvants like Freud’s complete adjuvant 
(FCA) and are optimal when used in conjunction with an immunogenic compound. 
Assuming the upper genital tract sequelae observed in our model is mediated, at least in 
part, by the host immune response, it is possible that the B6 TH1-bias was too much for 
alum adjuvant to overcome which manifested as mild disease. Secondly, but not less 
important, is the chlamydial preparation used in the study. Chlamydiae-derived outer 
membrane complex preparations were used as immunogen in the preliminary studies 
while whole viable organisms were used in the alum efficacy studies. This is important in 
that the alum alone immunized group scores (Figure 4-9) are indistinguishable from 
Chlamydia muridarum-alum and Chlamydia muridarum alone group scores.  In using 
concentrated COMC preparations, we directed the host response against known 
immunogenic proteins associated with the chlamydial membrane. Perhaps statistical 
differences were not observed amongst immunization groups, including alum alone, 
because we diversified the anti-chlamydial antibody pool by using whole organisms over 
purified COMC preparations.  While it is conceivable that either or both of these 
explanations contributed to differences seen in our alum efficacy experiments, further 
study is needed to draw definitive conclusions.  
 
While data presented in this Chapter would, seemingly, negate the hypothesis put 
forth in Chapter 2 relating to the potential benefits of having TH2-related IL-4 present late 
during recurrent infection that is not the case. Our hypothesis hinges on the idea that IL-4 
is detectable late during recurrent infection cycles as a way for chlamydial hosts to repair 
severe tissue damage.  In our studies, alum adjuvant was administered concurrently with 
chlamydial immunogen, prior to the development of severe upper genital tract 
complications. It is logically to hypothesize that a portion of time in which the host 
perceives ‘self-damage’ is necessary for the gearing up of potentially protective TH2-
related responses.  As stated previously, this is only a hypothesis albeit formed from data 
derived from ongoing chlamydial genital studies in our laboratory. The continuation and 
translational relevance of the studies reported in this Chapter are currently being 
investigated in our laboratory and are supported, at least in part, by the recent report 
published by Rodolfo et al suggesting an evolutionary genital tract bias for Th2 responses 
as a mechanism to prevent chlamydial-induced genital tract complications in humans 
[195].  
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CHAPTER 5.    CONCLUSIONS 
 
 
The reproductive health of women is of particular concern with current CDC 
Chlamydia surveillance data indicating increases in reported chlamydial infections, 
perhaps, in part, as a result of rapid antibiotic intervention. To this end, we interrogated 
the murine model for its potential to serve as a translational bridge between population-
based epidemiology and previous animal and human studies. Our studies reaffirm the 
benefit of rapid antibiotic intervention in Chlamydia control efforts and suggest an added 
benefit during repeated infection even in the absence of antibiotic treatment. Moreover, 
our results suggest a TH2-independent role for IL-4 in genital tract tissue repair.  
 
 
Testing the IL-4 Hypothesis 
 IL-4 as a mediator of TH2-driven immunity is well established but the role IL-4 
may play in genital tract tissue repair is largely unknown. In our studies we show 
elevated levels of systemic IL-4 late during recurrent chlamydial genital infection and 
cellular infiltrates that are known to produce IL-4 in the genital tract. We also show a 
correlation between systemic IL-4 and disease severity. To assess the role of IL-4 in the 
arrested immunity model, longitudinal studies are necessary. In these studies we would 
measure the onset, duration, and resolution of TH1 and TH2-linked cytokines and disease 
progression. This is important given the fact that tissue repair mechanisms rely on the 
presence of tissue damage. If IL-4 is indeed a driver of in vivo tissue repair, at least in 
this model, it is plausible that the production and secretion of the cytokine would begin 
with or after the development of chlamydial-induced pathology. Future studies should 
also measure IL-4 transcription levels in implicated cell types (mast cells and 
eosinophils) to confirm that they are the primary source of IL-4. These studies would be 
followed by IL-4 knockout studies that examine the effect of IL-4 on collateral tissue 
damage during multiple rounds of chlamydiae infection.  
 
 
Identifying Genetic Link to Age-Dependent Disease Severity 
 Studies are currently underway using B (C57BL/6) x D (DBA/2J) recombinant 
inbred mouse strains to identify genetic factors that may modulate disease susceptibility 
in an age-dependent manner. By interrogating the GeneNetwork database using a forward 
genomic approach, we hope to identify genes associated with the modulation of oviduct 
and uterine horn disease severity in an age and strain dependent manner. If disease 
severity is associated with specific genetic loci, human cell culture studies focused on 
RNA silencing will ensue. These studies will be followed with in vivo studies using 
knockout mice specific for the identified gene(s).  
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Implications for Vaccine Development 
 It is generally accepted that an effective anti-chlamydial vaccine would need to 
elicit a robust TH1-type CD4+ T cell response but our studies suggest that prophylactic 
control of chlamydiae may be more complex than originally appreciated. If the goal is to 
clear the pathogen from the site of infection and minimize the likelihood of developing 
adverse reproductive upper genital tract complications, eliciting TH1-linked immune 
responses may not be enough. It may be beneficial for the host to mount a mixed 
immunological response (I.E. TH1/ TH2). Our work highlights the need for additional 
studies aimed at addressing the role of mixed cell-mediated responses in chlamydial 
infection and immunopathological genital tract damage.  
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APPENDIX A. MORBIDITY AND PATHOLOGY SEVERITY POST-
PRIMARY INFECTION IN DEFERRED TREATMENT STUDIES 
 
 
 
 
Note: C57BL/6 female mice were purchased from Jackson Laboratories at 7-8 weeks of 
age. Animals were subcutaneously treated with progesterone at days 14 and 7 per 
intravaginal challenge. On day 0, animals were intravaginally challenged with 2 x 103 
IFU C. muridarum.  UN refers to animals that did not receive treatment during the 
courseo f the experiment. (0-14) represents animals that were intraperitoneally treated 
with doxycycline starting at day 0 for 14 days consecutively. (2-16) represents animals 
that were intraperitoneally treated with doxycycline starting 2 days post primary 
challenge for 14 days consecutively. (4-18) represents animals that were intraperitoneally 
treated with doxycycline starting on day 4 post primary challenge for 14 days 
consecutively. Normal represents negative the negative control group which neither 
received treatment nor intravaginal Chlamydia muridarum challenge. Animals were 
sacrificed 56 post-primary infection.  
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APPENDIX B. MORBIDITY AND PATHOLOGY SEVERITY POST- 
SECONDARY INFECTION IN DEFERRED TREATMENT STUDIES 
 
 
 
Note:  C57BL/6 female mice were purchased from Jackson Laboratories at 7-8 weeks of 
age. Animals were subcutaneously treated with progesterone at days 14 and 7 per 
intravaginal challenge. On day 0, animals were intravaginally challenged with 2 x 103 
IFU C. muridarum.  UN refers to animals that did not receive treatment during the course 
of the experiment. (0-14) represents animals that were intraperitoneally treated with 
doxycycline starting at day 0 for 14 days consecutively. (2-16) represents animals that 
were intraperitoneally treated with doxycycline starting 2 days post primary challenge for 
14 days consecutively. (4-18) represents animals that were intraperitoneally treated with 
doxycycline starting on day 4 post primary challenge for 14 days consecutively. Normal 
represents negative the negative control group which neither received treatment nor 
intravaginal Chlamydia muridarum challenge. Animals were sacrificed 56 post-
secondary infection.  
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APPENDIX C. TH1-RELATED CYOKINES POST RECURRENT 
INFECTION IN ARRESTED IMMUNITY MODEL 
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APPENDIX D. TH2-RELATED CYTOKINES POST RECURRENT 
INFECTION IN ARRESTED IMMUNITY MODEL 
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